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Abstract  1 
Currently there are no effective antifibrotic therapies for liver cirrhosis, a major killer 2 
worldwide. To obtain a cellular resolution of directly-relevant pathogenesis and to 3 
inform therapeutic design, we profile the transcriptomes of over 100,000 primary 4 
human single cells, yielding molecular definitions for the major non-parenchymal cell 5 
types present in healthy and cirrhotic human liver. We uncover a novel scar-associated 6 
TREM2+CD9+ macrophage subpopulation, which expands in human and mouse liver 7 
fibrosis, has a distinct differentiation trajectory from circulating monocytes and 8 
displays a pro-fibrogenic phenotype. In the endothelial compartment, we show that 9 
newly-defined ACKR1+ and PLVAP+ endothelial cells expand in cirrhosis, are 10 
topographically located in the fibrotic septae and enhance leucocyte transmigration. 11 
Multi-lineage ligand-receptor modelling of specific interactions between the novel 12 
scar-associated macrophages, endothelial cells and PDGFRα+ collagen-producing 13 
mesenchymal cells in the fibrotic niche, reveals intra-scar activity of several major pro-14 
fibrogenic pathways including TNFRSF12A, PDGFR and NOTCH signalling. Our 15 
work dissects unanticipated aspects of the cellular and molecular basis of human organ 16 
fibrosis at a single-cell level, and provides the conceptual framework required to 17 





Liver cirrhosis is a major global healthcare burden. Recent estimates suggest that 844 20 
million people worldwide have chronic liver disease, with a mortality rate of two 21 
million deaths per year and a rising incidence1. In health, the liver serves a myriad of 22 
functions including detoxification, metabolism, bile production and immune 23 
surveillance. Chronic liver disease, the result of iterative liver injury secondary to any 24 
cause, results in progressive fibrosis, disrupted hepatic architecture, vascular changes 25 
and aberrant regeneration, defining characteristics of liver cirrhosis2. Importantly, the 26 
degree of liver fibrosis predicts adverse patient outcomes, including the development 27 
of cirrhosis-related complications, hepatocellular carcinoma and death3. Hence, there is 28 
a clear therapeutic imperative to develop effective anti-fibrotic approaches for patients 29 
with chronic liver disease4–7. 30 
Liver fibrosis involves a complex, orchestrated interplay between multiple non-31 
parenchymal cell (NPC) lineages including immune, endothelial and mesenchymal 32 
cells spatially located within areas of scarring, termed the fibrotic niche. Despite rapid 33 
progress in our understanding of the cellular interactions underlying liver fibrogenesis 34 
accrued using rodent models, there remains a significant 'translational gap' between 35 
putative targets and effective patient therapies4,5. This is in part due to the very limited 36 
definition of the functional heterogeneity and interactome of cell lineages that 37 
contribute to the fibrotic niche of human liver cirrhosis, which is imperfectly 38 
recapitulated by rodent models4,6. 39 
Single-cell RNA sequencing (scRNA-seq) has the potential to deliver a step change in 40 
both our understanding of healthy tissue homeostasis as well as disease pathogenesis, 41 
allowing the interrogation of individual cell populations at unprecedented resolution8–42 
11. Here, we have studied the mechanisms regulating human liver cirrhosis, using 43 
scRNA-seq to analyse the transcriptomes of 106,616 single cells obtained from ten 44 
healthy and cirrhotic human livers and peripheral blood. 45 
Our data define: (1) a single-cell atlas of non-parenchymal cells in healthy and cirrhotic 46 
human liver; (2) a new subpopulation of scar-associated TREM2+CD9+ pro-fibrogenic 47 




endothelial cells; and (4) key ligand-receptor interactions between novel scar-49 
associated macrophages, endothelial subpopulations and collagen-producing 50 
myofibroblasts in the fibrotic niche. Thus, we have simultaneously identified a series 51 
of intra-scar pro-fibrogenic pathways which represent hitherto unsuspected therapeutic 52 
targets for the treatment of liver fibrosis, whilst demonstrating the applicability of 53 
scRNA-seq to define pathogenic mechanisms for other human fibrotic disorders. 54 
Results 55 
Single-cell atlas of human liver non-parenchymal cells  56 
Hepatic NPC were isolated from fresh healthy and cirrhotic human liver tissue spanning 57 
a range of aetiologies of cirrhosis (Fig. 1a, Extended Data Fig. 1a). Importantly, to 58 
minimise artefacts12, we developed a rapid tissue processing pipeline, obtaining fresh 59 
non-ischaemic liver tissue taken by wedge biopsy prior to the interruption of the hepatic 60 
vascular inflow during liver surgery or transplantation, and immediately processing this 61 
for FACS. This enabled a workflow time of under three hours from patient to single-62 
cell droplet encapsulation (Methods).  63 
We used an unbiased approach, FACS sorting viable single cells from liver tissue into 64 
broad leucocyte (CD45+) or other NPC (CD45-) fractions (Extended Data Fig. 1b), prior 65 
to scRNA-seq. To facilitate discrimination between liver-resident and circulating 66 
leucocytes, we also performed scRNA-seq on CD45+CD66b- peripheral blood 67 
mononuclear cells (PBMCs) (Extended Data Fig. 1c, f). In total, we analysed 67,494 68 
human cells from healthy (n=5) and cirrhotic (n=5) livers, 30,741 PBMCs from 69 
cirrhotic patients (n=4) and compared our data with a publicly-available reference 70 
dataset of 8,381 PBMCs from a healthy donor. 71 
Tissue cells and PBMCs could be partitioned into 21 distinct clusters, which we 72 
visualized using t-distributed stochastic neighbourhood embedding (t-SNE) (Extended 73 
Data Fig. 1d). Clusters were annotated using signatures and integrating with known 74 
lineage markers (Extended Data Fig. 1e; signature gene lists available in Supplementary 75 
Table 1). All PBMC datasets contained the major blood lineages, with excellent 76 




liver-resident cells, contaminating circulating cells were removed from the liver tissue 78 
datasets, by excluding individual cells from the tissue samples which mapped 79 
transcriptionally to blood-derived clusters 1 and 13 (Extended Data Fig. 1d).  80 
Re-clustering the 66,135 liver-resident cells revealed 21 clusters (Fig. 1b), each 81 
containing cells from both healthy and cirrhotic livers (Fig. 1c). Gene signature analysis 82 
enabled annotation of each cluster by major cell lineage (Fig. 1d, Extended Data Fig. 83 
2a, b). We noted heterogeneity in the post-normalised detected number of genes and 84 
unique molecular identifiers (UMIs) per cell, dependent on cell lineage (Extended Data 85 
Fig. 2c, d). All samples contained the expected cell lineages (Extended Data Fig. 2e, g) 86 
and reproducibility between livers was excellent for the main NPC populations 87 
(Extended Data Fig. 2f). 88 
We used an area-under-curve classifier to identify cell subpopulation markers across 89 
all 21 clusters and 11 lineages (Fig. 1e; Supplementary Tables 2 and 3). Expression of 90 
collagens type I and type III, the main extracellular matrix components of the fibrotic 91 
niche, was restricted to cells of the mesenchymal lineage (Fig. 1e). To gain further 92 
resolution on NPC heterogeneity, we then iterated clustering and marker gene 93 
identification on each lineage in turn, for example defining 11 clusters of T cells and 94 
innate lymphoid cells (ILCs) (Extended Data Fig. 3a) and four clusters of B cells and 95 
plasma cells (Extended Data Fig. 3f, g, Supplementary Table 6). No major differences 96 
in B cell or plasma cell composition between healthy and cirrhotic livers were observed 97 
(Extended Data Fig. 3h), and plasmacytoid dendritic cells (pDC) showed no additional 98 
heterogeneity. 99 
To further annotate the 11 T cell and ILC clusters (36,900 cells from 10 livers) we 100 
assessed expression of known markers (Extended Data Fig. 3c) and computationally 101 
identified differential marker genes (Extended Data Fig. 3d, Supplementary Table 4). 102 
We also performed imputation of gene dropouts, which enhanced detection of 103 
discriminatory marker genes for each cluster but did not yield additional T cell or ILC 104 
subpopulations (Extended Data Fig. 3e, Supplementary Table 5). All T cell and ILC 105 
clusters expressed tissue residency markers CD69 and CXCR4. Clusters 1 and 2 were 106 
CD4+ T cells, with CD4+ T cell(2) expanding significantly in cirrhotic livers (Extended 107 




CD4+ T cells in liver cirrhosis. Sparse expression of FOXP3, RORC, IL17A and IFNG 109 
in both CD4+ T cell subpopulations suggested the presence of Tregs, Th17 and Th1 110 
cells in these clusters. Clusters 3, 4 and 5 were CD8+ T cells, with features of effector 111 
T cells expressing GZMA, GZMH and IFNG. Two resident CD56bright IL7R- NK cell 112 
clusters were defined (NK cell(1) and NK cell(2)), as well as a distinct cytotoxic 113 
CD56dim NK cell population (cNK), with specific expression of FCGR3A and GZMB. 114 
No expansion of these populations was observed in cirrhotic livers. 115 
We provide an interactive gene browser freely-available online 116 
(http://www.livercellatlas.mvm.ed.ac.uk), to allow assessment of individual gene 117 
expression both in all human liver NPC and in specific lineages, comparing healthy 118 
versus cirrhotic livers. 119 
(Note to referees: http://www.livercellatlas.mvm.ed.ac.uk will be made freely 120 
available. For review purposes, log-in details are username: Edinburghlivercellatlas; 121 
password: Cirrhosis;  please refresh your browser if the webpage does not load at first 122 
attempt.) 123 
Distinct macrophage subpopulations inhabit the fibrotic niche  124 
Macrophages are critical to tissue homeostasis and wound-healing13. Previous studies 125 
have highlighted phenotypically-distinct macrophage populations orchestrating both 126 
liver fibrosis progression and regression in rodent models14,15, with preliminary 127 
evidence of heterogeneity in fibrotic human livers16. Here, we define unique 128 
subpopulations of macrophages which populate the fibrotic niche of cirrhotic human 129 
livers. Unsupervised clustering of all 10,737 mononuclear phagocytes (1,074±153 cells 130 
from each liver), isolated from the combined liver-resident cell dataset, identified nine 131 
MP clusters and one cluster of proliferating MP cells (Fig. 2a). We annotated these nine 132 
clusters as subpopulations of scar-associated macrophages (SAM), Kupffer cells (KC), 133 
tissue monocytes (TMo), and conventional dendritic cells (cDC) (Fig. 2a; see below). 134 
Strikingly, clusters MP(4) and MP(5), named SAM(1) and SAM(2) respectively, were 135 
expanded in cirrhotic livers (Fig. 2b), a finding that was confirmed by quantification of 136 
the MP cell composition of each liver individually (Fig. 2c), and reproduced in all 137 




To enable MP cell annotation, we initially assessed expression of known MP marker 139 
genes (Extended Data Fig. 4a), classifying clusters MP(8) and MP(9) as conventional 140 
dendritic cells, cDC2 and cDC1 respectively, based on CD1C and CLEC9A specificity. 141 
However, the remaining markers did not demarcate the other monocyte and 142 
macrophage subpopulations. Instead, these were identified using differential expression 143 
analysis across all MP clusters (Fig. 2d, Supplementary Table 7).  Clusters MP(1), 144 
MP(2) and MP(3) were distinguished by expression of S100 genes, FCN1, MNDA and 145 
LYZ, in keeping with a tissue monocyte (TMo) phenotype and informing annotation as 146 
TMo(1), TMo(2) and TMo(3) respectively (Fig. 2d, e, Extended Data Fig. 4a, 147 
Supplementary Table 7).  148 
Clusters MP(6) and MP(7) were enriched in CD163, MARCO, TIMD4 and CD5L 149 
(Extended Data Fig. 4b); multiplex immunofluorescence staining confirmed these as 150 
Kupffer cells (KC; resident liver macrophages), facilitating annotation of these clusters 151 
as KC(1) and KC(2) respectively (Extended Data Fig. 4c). Application of these markers 152 
enabled the definitive distinction between KC and other MP cells for the first time in 153 
human liver tissue. KC displayed characteristic morphology and sinusoidal topography 154 
in healthy livers but were absent from areas of scarring in cirrhotic livers (Extended 155 
Data Fig. 4c). A lack of TIMD4 expression distinguished KC(2) from KC(1) (Extended 156 
Data Fig. 4b); CD163+MARCO+TIMD4- cells were identifiable in healthy livers but 157 
rare in cirrhotic livers (Extended Data Fig. 4c), concordant with a significant reduction 158 
of KC(2) cells in cirrhosis (Fig. 2c). Automated histological cell counting demonstrated 159 
TIMD4+ cell numbers to be equivalent between healthy and cirrhotic livers, but showed 160 
a loss of MARCO+ cells, consistent with selective reduction in MARCO+TIMD4- KC 161 
in liver fibrosis (Extended Data Fig. 4d, e).  162 
Scar-associated clusters SAM(1) and SAM(2), expanded in diseased livers and 163 
expressed the unique markers TREM2 and CD9 (Fig. 2c-e). These newly-defined 164 
macrophages displayed a hybrid phenotype, with features of both tissue monocytes and 165 
KC (Fig. 2d, e), analogous to monocyte-derived macrophages in murine liver injury 166 
models15,17. Multi-colour flow cytometry confirmed expansion of these TREM2+CD9+ 167 
macrophages in human fibrotic livers (Fig. 2f, Extended Data Fig. 4f). Tissue 168 




(smFISH) demonstrated the presence of TREM2+MNDA+ and CD9+MNDA+ 170 
macrophages in fibrotic livers (Extended Data Fig. 4g-i). Multiplex 171 
immunofluorescence further confirmed the presence of TREM2+CD9+ cells localised 172 
in collagen-positive scar regions in cirrhotic livers (Fig. 2g), and automated cell 173 
counting of stained sections confirmed expansion of TREM2+ and CD9+ cells in 174 
cirrhotic livers (Fig. 2h, i).  175 
Strikingly, TREM2+ and CD9+ cells were rarely identified in the parenchyma of healthy 176 
livers, but were consistently located within areas of scar in cirrhotic livers. To confirm 177 
this, automated cell counting was applied to immunohistochemically-stained cirrhotic 178 
livers morphologically segmented into regions of fibrotic septae and parenchymal 179 
nodules (Fig. 2j). This demonstrated a significant accumulation of TREM2+ and CD9+ 180 
cells in fibrotic regions, whilst negligible numbers of KC populated the fibrotic septae 181 
(Fig. 2j). Hence, we annotated TREM2+CD9+ MP cells as scar-associated macrophages 182 
(SAM). 183 
Local proliferation has been shown to play a significant role in the expansion of 184 
macrophage subpopulations at sites of inflammation and fibrosis in experimental rodent 185 
models15,18,19, but has not been extensively characterised in human inflammatory 186 
disorders. To investigate MP proliferation in human liver fibrosis, we isolated the 187 
cycling MP cluster (Fig. 2a; cluster 10), which was enriched for multiple cell cycle-188 
related genes (Supplementary Table 7). Cycling MP cells subclustered into four, 189 
yielding cDC1, cDC2, KC and SAM subpopulations (Extended Data Fig. 4j). We 190 
observed a significant expansion of cycling SAM in cirrhosis, representing 1.70±0.52% 191 
of total TREM2+ MP cells in cirrhotic livers (Extended Data Fig. 4k). In contrast 192 
0.99±0.63% of KC were proliferating in healthy livers, with none detected in cirrhotic 193 
livers (Extended Data Fig. 4k). These data highlight the potential role of local 194 
macrophage proliferation in driving the accumulation of SAM in the fibrotic niche of 195 
human chronic liver disease. 196 
Pro-fibrogenic phenotype of scar-associated macrophages  197 
To delineate the functional profile of SAM we generated self-organising maps using 198 




subpopulations. This created a landscape of 3600 metagenes on a 60x60 grid and 200 
highlighted 44 metagene signatures overexpressed in the MP lineage (Fig. 3a). 201 
Mapping the nine MP cell clusters to this landscape (Extended Data Fig. 5a) identified 202 
six optimally-differentiating metagene signatures, denoted as A-F (Fig. 3a, 203 
Supplementary Table 8). Signatures A and B defined the scar-associated macrophages 204 
and were enriched for ontology terms relevant to tissue fibrosis and associated 205 
processes such as angiogenesis, in addition to known macrophage functions such as 206 
phagocytosis and antigen processing (Fig. 3b). These SAM-defining signatures 207 
included genes such as TREM2, IL1B, SPP1, LGALS3, CXCR4, CCR2, and TNFSF12; 208 
a number of which are known to regulate the function of scar-producing myofibroblasts 209 
in fibrotic liver diseases20–25. The remaining MP subpopulations were defined by 210 
signature C (KC), signatures D, E (TMo) and signature F (cDC1); ontology terms 211 
matched known functions for the associated cell type (Fig. 3b, Extended Data Fig. 5b, 212 
Supplementary Table 8). In particular, the KC clusters showed significant enrichment 213 
for ontology terms involving endocytosis, lipid and iron homeostasis, known functions 214 
of KC in mice26. Importantly, macrophage populations did not conform to either an M1 215 
or M2 phenotype, again highlighting the limitation of this classification. 216 
In mice, there are two main origins of hepatic macrophages, either embryologically-217 
derived or monocyte-derived27. Under homeostatic conditions, tissue-resident KC 218 
predominate and are embryologically-derived self-renewing cells28–32. However, 219 
following liver injury, macrophages derived from the recruitment and differentiation of 220 
circulating monocytes accumulate in the liver and regulate hepatic fibrosis15,33. The 221 
ontogeny of human hepatic macrophage subpopulations has never previously been 222 
investigated. Scar-associated TREM2+CD9+ macrophages demonstrated a monocyte-223 
like morphology (Fig. 2g, Extended Data Fig. 4g-i) and a distinct topographical 224 
distribution from KC (Fig. 2j), suggesting they may represent monocyte-derived cells. 225 
To computationally assess the origin of these SAM, we performed in silico trajectory 226 
analysis on a combined dataset of peripheral blood monocytes and liver-resident MPs. 227 
We visualised the transcriptional profile of these cells using a diffusion map, mapped 228 
them along a pseudotemporal trajectory (using the monocle R package) and interrogated 229 
their directionality via spliced and unspliced mRNA ratios (RNA velocity34,35) (Fig. 230 




blood monocytes into either SAM or cDC (Fig. 3c). Additionally, applying RNA 232 
velocity indicated a lack of differentiation from KC to SAM, and no progression from 233 
SAM to KC (Fig. 3c).  234 
To further investigate the pseudotemporal relationship between SAM and KC, we 235 
visualised the combined blood monocyte and liver-resident MP dataset using a UMAP, 236 
and performed additional RNA velocity analyses34,35 (Fig. 3d).  Evaluation of spliced 237 
and unspliced mRNAs showed expected downregulation (negative velocity) of 238 
monocyte gene MNDA in SAM, expected upregulation (positive velocity) of SAM 239 
marker gene CD9 in tissue monocytes, and a lack of KC gene TIMD4 velocity in SAM 240 
(Fig. 3e). This infers an absence of pseudotemporal dynamics between KC and SAM. 241 
Furthermore, assessment of the probabilities of cells in this dataset transitioning into 242 
SAM, indicated a higher likelihood of tissue monocytes than KC differentiating into 243 
SAM (Fig. 3f). Overall, these data suggest that scar-associated macrophages in human 244 
fibrotic liver are monocyte-derived, and imply that SAM represent a terminally-245 
differentiated cell state within the fibrotic niche. 246 
To further characterise the phenotype of scar-associated macrophages, we identified 247 
differentially expressed genes along the branching monocyte differentiation trajectories 248 
(Fig. 3g). We defined three gene co-expression modules by hierarchical clustering, with 249 
module 1 representing genes that are upregulated during blood monocyte-to-SAM 250 
differentiation (Fig. 3g). Module 1 was over-expressed in SAM, and contained multiple 251 
pro-fibrogenic genes including SPP1, LGALS3, CCL2, CXCL8, PDGFB and VEGFA20–252 
23,36–38(Fig. 3h). Analogous to signatures A and B (Fig. 3b), module 1 displayed 253 
ontology terms consistent with promoting tissue fibrosis and angiogenesis, including 254 
the regulation of other relevant cell types such as fibroblasts and endothelial cells (Fig. 255 
3h). Co-expression module 2 contained genes that were downregulated during 256 
monocyte-to-SAM differentiation, confirming a loss of characteristic monocyte genes 257 
(Extended Data Fig. 5e). Module 3 encompassed a distinct group of genes that were 258 
upregulated during monocyte-to-cDC differentiation (Extended Data Fig. 5f). Full lists 259 
of genes and ontology terms for all three modules are available (Supplementary Table 260 
9). These data highlight that SAM acquire a specific pro-fibrogenic phenotype during 261 




To further assess the function of human SAM, macrophage subpopulations were 263 
isolated from cirrhotic human livers by FACS (Fig. 2f, Extended Data Fig. 4f). SAM 264 
demonstrated enhanced protein secretion of several of the mediators identified by 265 
transcriptional analysis (Extended Data Fig. 5c). Additionally, conditioned media from 266 
SAM promoted fibrillar collagen expression by primary human hepatic stellate cells 267 
(HSC) (Extended Data Fig. 5d), confirming that SAM have a pro-fibrogenic phenotype. 268 
To enable cross-species comparison, we performed scRNA-seq on liver MP cells 269 
isolated from control (uninjured) mice or mice treated with chronic carbon tetrachloride 270 
(CCl4), a well-established mouse model of liver fibrosis15. MP cells from fibrotic livers 271 
were isolated 24 hours following the final CCl4 injection, a time of active fibrogenesis15. 272 
Five clusters of MP cells were defined (Extended Data Fig. 6a), with differentially 273 
expressed marker genes (Extended Data Fig. 6c, d, Supplementary Table 10) which 274 
facilitated cell type annotation (Extended Data Fig. 6a). An injury-specific macrophage 275 
population, cluster mMP(2), was identified (Extended Data Fig. 6a, b) and was 276 
differentiated by high expression of Cd9, Trem2, Spp1 and Lgals3 (Extended Data Fig. 277 
6c, d). We confirmed expansion of this murine CD9+ SAM (mSAM) population in liver 278 
fibrosis (Extended Data Fig. 6e, f). Co-culture of mSAM with quiescent primary murine 279 
HSC promoted fibrillar collagen expression in HSC (Extended Data Fig. 6g), indicating 280 
a pro-fibrogenic phenotype of mSAM. To confirm that mSAM represent the corollary 281 
population to human SAM (hSAM), we performed an unbiased canonical correlation 282 
analysis (CCA) between human and mouse MP datasets39. Both hSAM and mSAM 283 
clustered together (h&mMP(2); Extended Data Fig. 6h,i) and this cluster was enriched 284 
for the SAM markers CD9, TREM2 and SPP1 (Extended Data Fig. 6j). Similar cross-285 
species conservation was also observed for KC (h&mMP(3); Extended Data Fig. 6h-j). 286 
To identify potential transcriptional regulators of human SAM we used the SCENIC 287 
package to define sets of genes co-expressed with known transcription factors, termed 288 
regulons. We assessed the cell activity score for differentially-expressed regulons along 289 
the tissue monocyte-macrophage pseudotemporal trajectory and in KC, allowing 290 
visualisation of regulon activity across liver-resident macrophage subpopulations 291 
(Extended Data Fig. 5g, h, Supplementary Table 11). This identified regulons and 292 




highlighting NR1H3 and SPIC activity in human KC (Extended Data Fig. 5g, h), which 294 
are known to regulate KC function in mice40,41. Scar-associated macrophages are 295 
enriched for regulons containing the transcription factors HES1 and EGR2 (Extended 296 
Data Fig. 5g, h), both of which have been associated with modulation of macrophage 297 
phenotype and tissue fibrosis42–45. 298 
To determine whether SAM also expand in earlier stage human liver disease, we 299 
analysed cohorts of patients with non-alcoholic fatty liver disease (NAFLD). We 300 
applied differential gene expression signatures of human SAM, KC and TMo to a 301 
deconvolution algorithm46, which enabled the assessment of the hepatic monocyte-302 
macrophage composition in whole liver microarray data across the spectrum of early-303 
stage NAFLD severity47 (Extended Data Fig. 7a). This demonstrated an expansion of 304 
SAM in patients with non-alcoholic steatohepatitis (NASH) (Extended Data Fig. 7a, b), 305 
with an increased frequency of SAM with worsening histological NASH activity (NAS) 306 
and fibrosis scores (Extended Data Fig. 7c). No association was observed between 307 
SAM frequency and patient demographics such as gender, age or body mass index 308 
(Extended Data Fig. 7d). We were also able to histologically identify SAM in a locally 309 
generated NASH biopsy cohort (Extended Data Fig. 7e). SAM expansion increased 310 
with NASH activity (Extended Data Fig. 7e) and there was a positive correlation 311 
between SAM number and degree of fibrosis across the full severity spectrum of 312 
NAFLD-induced liver fibrosis (Extended Data Fig. 7f). 313 
In summary, multimodal computational, functional and histological analysis 314 
demonstrates that TREM2+CD9+ scar-associated macrophages derive from the 315 
recruitment and differentiation of circulating monocytes, are conserved across species, 316 
display a pro-fibrogenic phenotype and expand early in the course of liver disease 317 
progression. 318 
Distinct endothelial subpopulations inhabit the fibrotic niche  319 
In rodent models, hepatic endothelial cells are known to regulate both fibrogenesis48,49 320 
and macrophage recruitment to the fibrotic niche37. Unsupervised clustering of human 321 
liver endothelial cells identified seven subpopulations (Fig. 4a). Clusters Endo(6) and 322 




contracted (Fig. 4a, b). Classical endothelial cell markers did not discriminate between 324 
the seven clusters, although Endo(1) was distinct in lacking CD34 expression 325 
(Extended Data Fig. 8a).  In order to fully annotate endothelial subpopulations 326 
(Extended Data Fig. 8h), we identified differentially expressed markers (Fig. 4c, 327 
Supplementary Table 12), determined functional expression profiles (Extended Data 328 
Fig. 8g, Supplementary Table 13), performed transcription factor regulon analysis (Fig. 329 
4g, Supplementary Table 14) and assessed spatial distribution via multiplex 330 
immunofluorescence staining (Fig. 4d, e). 331 
Disease-specific endothelial cells Endo(6) and Endo(7), CD34+PLVAP+VWA1+ and 332 
CD34+PLVAP+ACKR1+ respectively (Fig. 4c, Extended Data Fig. 8b), expanded in  333 
cirrhotic liver tissue (Fig. 4f) and were spatially restricted to the fibrotic niche (Fig. 4d, 334 
e, Extended Data Fig. 8c), allowing their annotation as scar-associated endothelia 335 
SAEndo(1) and SAEndo(2) respectively. Scar-associated endothelial cells displayed 336 
enhanced expression of the ELK3 regulon (Fig. 4g), a transcription factor known to 337 
modulate angiogenesis50. Metagene signature analysis found that Endo(6) (SAEndo(1)) 338 
cells expressed pro-fibrogenic genes including PDGFD, PDGFB, LOX, LOXL2 and 339 
several basement membrane components51–53; associated significant ontology terms 340 
included extracellular matrix organization and wound healing (signature A; Extended 341 
Data Fig. 8g). Endo(7) (SAEndo(2)) cells displayed an immunomodulatory phenotype 342 
(signature B; Extended Data Fig. 8g). Furthermore, the most discriminatory marker for 343 
this cluster, ACKR1, is restricted to venules in mice54 and has a role in regulating 344 
leucocyte recruitment55. We isolated endothelial cells from healthy and cirrhotic human 345 
livers and confirmed increased expression of PLVAP, CD34 and ACKR1 on cells from 346 
diseased livers (Extended Data Fig. 8d). Flow-based adhesion assays56 demonstrated 347 
that cirrhotic endothelial cells showed enhanced leucocyte transmigration (Extended 348 
Data Fig. 8e), an effect that was attenuated by ACKR1 knockdown (Extended Data Fig. 349 
8f). These data demonstrate that SAEndo regulate inflammatory cell recruitment to the 350 
fibrotic niche. 351 
Using CLEC4M as a discriminatory marker of cluster Endo(1) (Fig. 4c, Extended Data 352 
Fig. 8b), immunofluorescence confirmed these CLEC4M+CD34- cells as liver 353 




parenchyma (Fig. 4d). Cluster Endo(1) demonstrated known features of LSEC, 355 
including GATA4 transcription factor regulon expression57 (Fig. 4g), and a metagene 356 
signature enriched for ontology terms including endocytosis and immune response58 357 
(signature D, Extended Data Fig. 8g). There was a reduction in CLEC4M staining in 358 
cirrhotic livers with an absence in fibrotic septae (Fig. 4d, f), indicating that LSEC do 359 
not inhabit the fibrotic niche in chronic liver disease. This was further supported by 360 
trajectory analysis, suggesting a lack of clear pseudotemporal dynamics between the 361 
LSEC and clusters SAEndo(1) and SAEndo(2) (Extended Data Fig. 8i). 362 
We annotated cluster Endo(2) (PDPN+CD34+PLVAP-) as lymphatic endothelial cells 363 
based on marker gene expression, relevant ontology terms (signature E; Extended Data 364 
Fig. 8g) and FOXC2 and HOXD8 regulon activity (Fig. 4g)59,60. Lymphatics populated 365 
the portal region of healthy livers (Fig. 4e). Hierarchical clustering of the endothelial 366 
subpopulations demonstrated that clusters Endo(3) and Endo(4) were closely related to 367 
LSEC (dendrogram not shown), co-expressing markers including CLEC4G (Extended 368 
Data Fig. 8b). Endo(4), defined as RSPO3+CD34+PLVAP+ (Fig. 4c, Extended Data Fig. 369 
8b), expressed a metagene signature overlapping with LSEC (signature D, Extended 370 
Data Fig. 8g), and were identified as central vein endothelial cells (Fig. 4e). This 371 
mirrors murine liver zonation data indicating RSPO3 as a marker of pericentral 372 
endothelial cells61. Similar to LSEC, central vein endothelial cells did not inhabit the 373 
fibrotic niche in cirrhosis (Fig. 4e). 374 
Cluster Endo(5), AIF1L+CD34+PLVAP+ cells, were mapped to periportal thick-walled 375 
vessels, consistent with hepatic arterial endothelial cells (Fig. 4e). Of note, these cells 376 
were also topographically associated with fibrotic septae in cirrhotic livers (Fig. 4e). 377 
The arterial identity of this cluster was further indicated by SOX17 regulon expression62 378 
(Fig. 4g), and it displayed a metagene signature enriched for Notch pathway ligands 379 
JAG1, JAG2 and DLL4; ontology terms included animal organ development, 380 
angiogenesis and Notch signalling (signature C; Extended Data Fig. 8g) in keeping with 381 
the known requirement of the Notch pathway in the development and maintenance of 382 
hepatic vasculature63. Endo(5) was annotated as HAEndo for subsequent analysis of 383 
cellular interactions within the fibrotic niche. 384 




PDGFRA expression defines scar-associated mesenchymal cells 386 
Hierarchical clustering of human liver mesenchymal cells identified four populations, 387 
including a population of mesothelial cells (Fig. 5a, b, Extended Data Fig. 9a, 388 
Supplementary Table 15). MYH11 expression distinguished cluster Mes(1) (Fig. 5b, 389 
Extended Data Fig. 9a), and labelled a population of vascular smooth muscle cells 390 
(VSMC) (Fig. 5c). Cluster Mes(2) expressed high levels of RGS5 (Fig. 5b, Extended 391 
Data Fig. 9a). RGS5 immunofluorescence staining demonstrated that these 392 
mesenchymal cells were located peri-sinusoidally (Fig. 5c), identifying this population 393 
as hepatic stellate cells (HSC)64. RGS5+ cells were absent from the fibrotic niche (Fig. 394 
5c). Cluster Mes(3) was distinguished by PDGFRA expression, in addition to high 395 
levels of fibrillar collagens and pro-fibrogenic genes such as TIMP1 and CCL2  (Fig. 396 
5b, d, Extended Data Fig. 9a).  PDGFRα+ cells expanded significantly in cirrhotic livers 397 
(Fig. 5a, e, f) and were spatially mapped to the fibrotic niche (Fig. 5f), enabling 398 
annotation as scar-associated mesenchymal cells (SAMes). 399 
To study heterogeneity within the SAMes population, further hierarchical clustering 400 
was performed on this population (Extended Data Fig. 9b). Two populations of SAMes 401 
were identified (Extended Data Fig. 9c, Supplementary Table 16), both of which 402 
expanded in cirrhotic livers (Extended Data Fig. 9d). OSR1, a marker of fibroblast 403 
subpopulations and regulator of extracellular matrix production65, distinguished a 404 
subpopulation of SAMes (Extended Data Fig. 9c), labelled a population of periportal 405 
cells in healthy liver (Extended Data Fig. 9e) and a subpopulation of scar-associated 406 
cells in the fibrotic niche (Extended Data Fig. 9f). These OSR1+ cells are likely to 407 
represent portal fibroblasts. 408 
In rodent models, HSC differentiate into scar-producing myofibroblasts following 409 
parenchymal liver injury66–68. We interrogated HSC differentiation in human liver 410 
tissue using pseudotemporal ordering and RNA velocity analyses between HSC and 411 
SAMes clusters, demonstrating a clear trajectory from HSC to SAMes (Extended Data 412 
Fig. 9g). Assessment of gene co-expression modules along the HSC-to-SAMes 413 
differentiation continuum indicated upregulation of fibrogenic genes including 414 




RGS5, IGFBP5, ADAMTS1 and GEM, which are known to be downregulated in murine 416 
HSC in response to liver injury67 (Extended Data Fig. 9h). 417 
Resolving the multi-lineage interactome in the fibrotic niche 418 
Having defined the scar-associated macrophage, endothelial and mesenchymal 419 
populations, we confirmed the close topographical association of these cells within the 420 
fibrotic niche (Fig. 6a, b). To interrogate how these newly-defined cellular 421 
subpopulations regulate fibrosis and to identify tractable therapeutic targets, we 422 
performed an unbiased ligand-receptor interaction analysis between these scar-423 
associated populations. We used CellPhoneDB, a repository of curated ligand-receptor 424 
interactions integrated with a statistical framework. We calculated statistically 425 
significant ligand-receptor pairs, based on expression of receptors by one lineage and 426 
ligands by another, using empirical shuffling69. 427 
Numerous statistically significant paracrine and autocrine interactions were detected 428 
between ligands and cognate receptors expressed by SAM, SAEndo and SAMes within 429 
the fibrotic niche (Supplementary Table 17). We focused further functional analyses on 430 
interactions with SAMes, the fibrillar collagen-producing population. Both SAM and 431 
SAEndo populations demonstrated multiple interactions that could regulate SAMes 432 
function (Extended Data Fig. 10a). In keeping with our data demonstrating that human 433 
and murine SAM promote fibrillar collagen expression in HSC (Extended Data Fig. 5d, 434 
Extended Fig. 6g), SAM expressed a number of epidermal growth factor receptor 435 
(EGFR) ligands which are known to regulate mesenchymal cell activation70,71. 436 
Additionally, SAM expressed mesenchymal cell mitogens TNFSF12 and PDGFB25,51, 437 
signaling to cognate receptors TNFRSF12A and PDGFRA on SAMes (Fig 6c). We 438 
confirmed localization of these ligand-receptor pairs within the fibrotic niche of human 439 
cirrhotic human liver (Fig. 6d, e). Both TNFSF12 and PDGF-BB induced primary 440 
human HSC proliferation, which was inhibited by blockade of TNFSF12A and 441 
PDGFRA respectively (Fig. 6f, g). Importantly, conditioned media from primary 442 
human SAM promoted primary human HSC proliferation ex vivo (Fig. 6h), 443 




SAEndo expressed high levels of non-canonical Notch ligands JAG1, JAG2 and DLL4 445 
interacting with Notch receptor NOTCH3 on SAMes (Fig. 6i). Primary endothelial cells 446 
from cirrhotic human liver demonstrated increased expression of JAG1 (Fig. 6j), whilst 447 
NOTCH3 was identified on PDGFRα+ SAMes within the fibrotic niche (Fig. 6k). Co-448 
culture of primary human HSC and endothelial cells from cirrhotic livers promoted 449 
fibrillar collagen production by HSC, which was inhibited by addition of the Notch-450 
signalling inhibitor Dibenzazepine (DBZ) (Fig. 6l, m). Furthermore, knockdown of 451 
NOTCH3 expression in primary human HSC resulted in reduced fibrillar collagen 452 
expression (Fig. 6n), confirming that Notch-signalling promotes a fibrogenic 453 
mesenchymal cell phenotype45. 454 
SAMes expressed a number of ligands demonstrating statistically significant 455 
interactions with receptors on SAM and SAEndo (Extended Data Fig. 10b). In 456 
particular, SAMes expressed chemokines such as CCL2, which regulates monocyte-457 
macrophage recruitment and phenotype (Extended Data Fig. 10c, d). Furthermore, 458 
immunoregulatory ligands such as IL34, CSF1 and CX3CL1 expressed by SAMes 459 
(Extended Data Fig. 10c) are known to modulate macrophage function, survival and 460 
proliferation72,73, potentially explaining the increased proliferation rate observed in 461 
human SAM (Extended Data Fig. 4j, k). Intrahepatic angiogenesis is associated with 462 
both degree of liver fibrosis and portal hypertension, a major clinical consequence of 463 
liver cirrhosis74. Our fibrotic niche interactome analysis confirmed a number of pro-464 
angiogenic interactions, with both SAMes (Extended Data Fig. 10c, d) and SAM 465 
(Extended Data Fig. 10e-g) expressing angiogenic ligands, with cognate receptors 466 
expressed by SAEndo. Additionally, SAEndo expressed CSF1 and CD200 (Extended 467 
Data Fig. 10h-j), suggestive of an immunomodulatory role. This is emphasized by the 468 
highly significant interactions detected between Notch ligand expression by SAEndo 469 
and NOTCH2 expression by SAM (Extended Data Fig. 10i, j). Vascular Notch ligand 470 
expression regulates monocyte-derived macrophage differentiation and macrophage 471 
function in tissue repair75, congruent with our data demonstrating upregulation of the 472 
transcription factor regulon for the Notch-target HES1, during differentiation from 473 
monocytes to SAM (Fig. 3h, Extended Data Fig. 5f, g). Hence, SAEndo are likely to 474 
regulate immune function as well as leucocyte recruitment to the fibrotic niche 475 




In summary, our unbiased dissection of the key ligand-receptor interactions between 477 
novel scar-associated macrophages, endothelial and mesenchymal cells in the fibrotic 478 
niche, highlights TNFRSF12A, PDGFRA and Notch signaling as important regulators 479 
of mesenchymal cell function and hepatic fibrogenesis. Therapeutic targeting of these 480 
intra-scar pathways represents a rational approach for the discovery of novel antifibrotic 481 
treatments for patients with chronic liver disease. 482 
Discussion  483 
The fibrotic niche has not previously been defined in human liver. Here, using scRNA-484 
seq and spatial mapping, we resolve the fibrotic niche of human liver cirrhosis, 485 
identifying novel pathogenic subpopulations of TREM2+CD9+ pro-fibrogenic 486 
macrophages, ACKR1+ and PLVAP+ endothelial cells and PDGFRα+ collagen-487 
producing myofibroblasts. We dissect a complex, pro-fibrotic interactome between 488 
multiple novel scar-associated cells and identify highly relevant intra-scar pathways 489 
that are potentially druggable. This multi-lineage single cell dataset of human liver 490 
cirrhosis should serve as a useful resource for the scientific community, and is freely 491 
available for interactive browsing at http://www.livercellatlas.mvm.ed.ac.uk 492 
Despite significant progress in our understanding of the molecular pathways driving 493 
liver fibrosis in rodent models, a lack of corollary studies in diseased human liver tissue 494 
has hindered translation into effective therapies, with currently no FDA or EMA-495 
approved antifibrotic treatments available. Our multi-lineage ligand-receptor analysis  496 
demonstrates the complexity of interactions within the fibrotic niche, highlighting 497 
exemplar pathways such as TNFRSF12A, PDGFR and NOTCH signalling as key 498 
regulators of mesenchymal cell function in fibrotic human liver. These data provide a 499 
conceptual framework for more rational studies of antifibrotic therapies in both pre-500 
clinical animal models and translational systems such as human liver organoid 501 
cultures5,76,77. Further, this unbiased multi-lineage approach should inform the design 502 
of combination therapies which will very likely be necessary to achieve effective 503 
antifibrotic potency5,6. 504 
Macrophages and endothelial cells are known to regulate liver fibrosis in rodent 505 
models14,20,24,48,49. However, little is known regarding the heterogeneity and precise 506 




both the accumulation of discrete monocyte-derived macrophage and endothelial cell 508 
populations in the fibrotic niche of cirrhotic livers, but also the persistence of spatially 509 
distinct, non-scar associated resident Kupffer cells and liver sinusoidal endothelial 510 
cells. This single-cell approach has important implications for therapy development; 511 
facilitating targeting of pathogenic cells without perturbing homeostatic function. 512 
In this era of precision medicine, where molecular profiling guides the development of 513 
highly targeted therapies, we used scRNA-seq to resolve the key non-parenchymal cell 514 
subclasses inhabiting the fibrotic niche of human liver cirrhosis. Application of our 515 
novel scar-associated cell markers could potentially inform molecular pathology-based 516 
patient stratification, which is fundamental to the prosecution of successful antifibrotic 517 
clinical trials. Our work illustrates the power of single-cell transcriptomics to decode 518 
the cellular and molecular basis of human organ fibrosis, providing a conceptual 519 
framework for the discovery of relevant and rational therapeutic targets to treat patients 520 
with a broad range of fibrotic diseases. 521 
Note to referees: 522 
http://www.livercellatlas.mvm.ed.ac.uk will be made freely available. For review 523 
purposes, log-in details are username: Edinburghlivercellatlas; password: Cirrhosis;  524 




Methods  526 
Study subjects 527 
Local approval for procuring human liver tissue and blood samples for scRNA-seq, 528 
flow cytometry and histological analysis was obtained from the NRS BioResource and 529 
Tissue Governance Unit (Study Number SR574), following review at the East of 530 
Scotland Research Ethics Service (Reference 15/ES/0094). All subjects provided 531 
written informed consent. Healthy background non-lesional liver tissue was obtained 532 
intraoperatively from patients undergoing surgical liver resection for solitary colorectal 533 
metastasis at the Hepatobiliary and Pancreatic Unit, Department of Clinical Surgery, 534 
Royal Infirmary of Edinburgh. Patients with a known history of chronic liver disease, 535 
abnormal liver function tests or those who had received systemic chemotherapy within 536 
the last four months were excluded from this cohort. Cirrhotic liver tissue was obtained 537 
intraoperatively from patients undergoing orthotopic liver transplantation at the 538 
Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh. Blood from patients with 539 
a confirmed diagnosis of liver cirrhosis were obtained from patients attending the 540 
Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh. Patients with liver 541 
cirrhosis due to viral hepatitis were excluded from the study. Patient demographics are 542 
summarised in Extended Data Fig. 1a. Isolation of primary hepatic macrophage 543 
subpopulations and endothelial cells from healthy and cirrhotic livers for cell culture 544 
and analysis of secreted mediators was performed at the University of Birmingham, 545 
UK. Local ethical approval was obtained (Reference  06/Q2708/11, 06/Q2702/61) and 546 
all patients provided written, informed consent. Liver tissue was acquired from 547 
explanted diseased livers from patients undergoing orthotopic liver transplantation, 548 
resected liver specimens or donor livers rejected for transplant at the Queen Elizabeth 549 
Hospital, Birmingham. For histological assessment of NAFLD biopsies, anonymised 550 
unstained formalin-fixed paraffin-embedded liver biopsy sections encompassing the 551 
complete NAFLD spectrum were provided by the Lothian NRS Human Annotated 552 
Bioresource under authority from the East of Scotland Research Ethics Service REC 1, 553 
reference 15/ES/0094. 554 




For human liver scRNA-seq and flow cytometry analysis, a wedge biopsy of non-556 
ischaemic fresh liver tissue (2-3 grams) was obtained by the operating surgeon, prior to 557 
interruption of the hepatic vascular inflow. This was immediately placed in HBSS 558 
(Gibco) on ice. The tissue was then transported directly to the laboratory and 559 
dissociation routinely commenced within 20 minutes of the liver biopsy. To enable 560 
paired histological assessment, a segment of each liver specimen was also fixed in 4% 561 
neutral-buffered formalin for 24 hours followed by paraffin-embedding. Additional 562 
liver samples, obtained via the same method, were fixed in an identical manner and 563 
used for further histological analysis. For human macrophage cell sorting and 564 
endothelial cell isolation, liver tissue (40 grams) was used from cirrhotic patients 565 
undergoing orthotopic liver transplantation or control samples from donor liver or liver 566 
resection specimens. 567 
Animals 568 
Adult male C57BL/6JCrl mice aged 8-10 weeks were purchased from Charles River. 569 
Mice were housed under specific pathogen-free conditions at the University of 570 
Edinburgh. All experiments were performed in accordance with UK Home Office 571 
regulations. Liver fibrosis was induced with 4 weeks (9 injections) of twice-weekly 572 
intraperitoneal carbon tetrachloride (CCl4) at a dose of 0.4 μl/g body weight, diluted 573 
1:3 in olive oil as previously described15. Liver tissue was harvested 24 hours following 574 
the final CCl4 injection, a time of active fibrogenesis15. Comparison was made to age-575 
matched uninjured mice.  576 
Preparation of single-cell suspensions 577 
For human liver scRNA-seq, liver tissue was minced with scissors and digested in 578 
5mg/ml pronase (Sigma-Aldrich, P5147-5G), 2.93mg/ml collagenase B (Roche, 579 
11088815001) and 1.9mg/ml DNase (Roche, 10104159001) at 37°C for 30 minutes 580 
with agitation (200–250 r.p.m.), then strained through a 120μm nybolt mesh along with 581 
PEB buffer (PBS, 0.1% BSA, and 2mM EDTA) including DNase (0.02mg/ml). 582 
Thereafter all processing was done at 4oC. The cell suspension was centrifuged at 400g 583 
for 7 minutes, supernatant removed, cell pellet resuspended in PEB buffer and DNase 584 




cell lysis was performed (BioLegend, 420301), followed by centrifugation (400g, 7 586 
minutes), resuspension in PEB buffer and straining through a 35μm filter. Following 587 
another centrifugation at 400g for 7 minutes, cells were blocked in 10% human serum 588 
(Sigma-Aldrich, H4522) for 10 minutes at 4oC prior to antibody staining.        589 
For both human liver macrophage flow cytometry analysis and cell sorting and mouse 590 
liver macrophage flow cytometry, cell sorting and scRNA-seq, single-cell suspensions 591 
were prepared as previously described, with minor modifications78. In brief, liver tissue 592 
was minced and digested in an enzyme cocktail 0.625 mg/ml collagenase D (Roche, 593 
11088882001), 0.85 mg/ml collagenase V (Sigma-Aldrich, C9263-1G), 1 mg/ml 594 
dispase (Gibco, Invitrogen, 17105-041), and 30 U/ml DNase (Roche, 10104159001) in 595 
RPMI-1640 at 37°C for 20 minutes (mouse) or 45 minutes (human) with agitation 596 
(200–250 r.p.m.), before being passed through a 100μm filter. Following red blood cell 597 
lysis (BioLegend, 420301), cells were washed in PEB buffer and passed through a 598 
35μm filter. Before the addition of antibodies, cells from human samples were blocked 599 
in 10% human serum (Sigma-Aldrich, H4522) and mouse samples were blocked in 600 
anti-mouse CD16/32 antibody (1:100; Biolegend, 101302) and 10% normal mouse 601 
serum (Sigma, M5905) for 10 minutes at 4 °C. 602 
For human PBMC scRNA-seq, 4.9ml peripheral venous blood samples were collected 603 
in EDTA-coated tubes (Sarstedt, S-MonovetteÒ 4.9ml K3E) and placed on ice. Blood 604 
samples were transferred into a 50ml Falcon tube. Following red cell lysis (Biolegend, 605 
420301), blood samples were then centrifuged at 500g for 5 minutes and supernatant 606 
was removed. Pelleted samples were then resuspended in staining buffer (PBS plus 2% 607 
BSA; Sigma-Aldrich) and centrifugation was repeated. Samples were then blocked in 608 
10% human serum (Sigma-Aldrich, H4522) in staining buffer on ice for 30 minutes. 609 
Cells were then resuspended in staining buffer and passed through a 35μm filter prior 610 
to antibody staining.   611 
Flow cytometry and cell sorting 612 
Incubation with primary antibodies was performed for 20 minutes at 4°C. All 613 
antibodies, conjugates, lot numbers and dilutions used in this study are presented in 614 




buffer. For both human macrophage flow cytometry analysis and cell sorting, cells were 616 
then incubated with streptavidin-BV711 for 20 minutes at 4°C (Biolegend 405241; 617 
Dilution 1:200). For human and mouse cell sorting (FACS) and mouse flow cytometry 618 
analysis, cell viability staining (DAPI; 1:1000 dilution) was then performed, 619 
immediately prior to acquiring the samples.  620 
Human cell sorting for scRNA-seq was performed on a BD Influx (Becton Dickinson, 621 
Basel, Switzerland). Viable single CD45+ (leucocytes) or CD45- (other non-622 
parenchymal cells) cells were sorted from human liver tissue (Extended Data Fig. 1b) 623 
and viable CD45+ CD66b- (PBMC) cells were sorted from peripheral blood (Extended 624 
Data Fig. 1c) and processed for droplet-based scRNA-seq. 625 
To generate conditioned media from cirrhotic liver macrophage subpopulations, cells 626 
were sorted on a BD FACSAriaTM Fusion (Becton Dickinson, Basel, Switzerland). 627 
Sorted SAM (viable CD45+Lin-HLA-DR+CD14+CD16+CD163-TREM2+CD9+), TMo 628 
(viable CD45+Lin- HLA-DR+CD14+CD16+CD163-TREM2-CD9-) and KC (viable 629 
CD45+Lin- HLA-DR+CD14+CD16+CD163+CD9-) were plated in 12-well plates 630 
(Corning, 3513) in DMEM (Gibco, 41965039) containing 2% FBS (Gibco, 10500056) 631 
at 1x106 cells/ml for 24 hours at 37°C 5%CO2. Control wells contained media alone. 632 
Conditioned media was collected, centrifuged at 400g for 10 minutes and supernatant 633 
stored at -80°C. 634 
For human macrophage flow cytometry analysis, following surface antibody staining, 635 
cells were stained with Zombie NIR fixable viability dye (Biolegend, 423105) 636 
according to manufacturers’ instructions. Cells were washed in PEB then fixed in IC 637 
fixation buffer (Thermo-Fisher, 00-8222-49) for 20 minutes at 4°C. Fixed samples were 638 
stored in PEB at 4°C until acquisition. Flow cytometry acquisition was performed on 639 
6-laser Fortessa flow cytometer (Becton Dickinson, Basel, Switzerland). The gating 640 
strategy is shown (Extended Data Fig. 4f, Fig. 2f). 641 
Mouse macrophage cell sorting for scRNA-seq and co-culture experiments was 642 
performed on a BD FACSAriaII (Becton Dickinson, Basel, Switzerland). For scRNA-643 
seq, viable CD45+ Lin(CD3, NK1.1, Ly6G, CD19)- cells were sorted from healthy 644 




transwell co-culture, viable CD45+ Lin- CD11b+ F4/80+ TIMD4- CD9+ (mSAM) or 646 
CD9- (mTMo) cells were sorted from CCl4-treated mice (Extended Data Fig. 6e). Flow 647 
cytometry analysis on macrophages from healthy and CCl4-treated mice was also 648 
performed on a BD FACSAriaII (Becton Dickinson, Basel, Switzerland), using the 649 
same gating strategy (Extended Data Fig. 6e). All flow cytometry data was analysed 650 
using Flowjo software (Treestar, Ashland, TN). 651 
Luminex Assay 652 
Detection of CCL2, Galectin-3, IL-1 beta, CXCL8 and Osteopontin (SPP1) proteins in 653 
conditioned media from human liver macrophage subpopulations was performed using 654 
a custom human luminex assay (R&D systems), according to the manufacturers 655 
protocol. Data was acquired using a Bio-PlexÒ 200 (Bio-Rad, UK) and is presented a 656 
median fluorescence intensity (MFI) for each analyte. 657 
Cell Culture 658 
Human hepatic stellate cell activation 659 
Primary human hepatic stellate cells (HSC) were purchased (ScienCell, 5300) and 660 
cultured in stellate cell medium (SteCM, ScienCell, 5301) on Poly-L-Lysine (Sigma, 661 
P4832) coated T75 tissue culture flasks, according to the suppliers protocol. All 662 
experiments were performed using cells between passage 3 and 5. For assessment of 663 
fibrillar collagen gene expression, HSC were plated at 75,000 cells per well in  24 well-664 
plates (Costar, 3524) in HSC media consisting of DMEM (Gibco, 21969-035) 665 
supplemented with 20 µM HEPES (Sigma, H3375,), 2 mM L-Glutamine (Gibco , 666 
25030-024), 1% Penicillin Streptomycin (Gibco, 15140-122, Gibco) and 2% Foetal 667 
Bovine Serum (FBS, Gibco, 10270). HSC were serum starved overnight (in HSC media 668 
without FBS), washed with PBS, then 250μl of conditioned media from primary human 669 
macrophage subpopulations added for 24 hours. HSC were harvested for RNA. 670 
Human hepatic stellate cell proliferation 671 
For proliferation assays, following serum starvation HSC were harvested using TrypLE 672 
Express (Gibco, Cat. no. 12604013), re-suspended in HSC media at 2.5x104/ml with 673 




seeded into 384 well plates (Greiner Bio-One, 781090) at 25μl per well. HSC were then 675 
treated with control media or (i) PDGF-BB (10ng/ml; Peprotech, 100-14B) or 676 
TNFSF12 (100ng/ml; Peprotech, 310-06-5) with or without the PDGFR⍺ inhibitor 677 
Crenolanib79 (1μM; Cayman chemicals, CAY1873), anti-TNRSF12A (2μg/ml; Life 678 
Technologies, 16-9018-82, clone ITEM-4), mouse IgG2b kappa isotype control 679 
antibody (2μg/ml; Life Technologies, 16-4732-82, clone eBMG2b) or vehicle control 680 
as indicated or (ii) conditioned media from human hepatic macrophage subpopulations 681 
as indicated. The final volume was 50μl for all conditions. Cells were then incubated 682 
in an Incucyte ZOOM live cell analysis system (Essen Biosciences) humidified at 37°C 683 
with 5% CO2 with imaging every 3 hours using the 10x optic for either 87 hours 684 
(recombinant cytokines/inhibitors) or 39 hours (macrophage conditioned media). 685 
Analysis was performed with the Incucyte proprietary analysis software (version 686 
2018A) by using machine learning to distinguish the individual nuclei (stained red by 687 
the NucLight Rapid Red dye) and perform nuclear counts of the images at each 3 hour 688 
time point over the period of culture. Data are expressed as area under curve (AUC) 689 
for % change in nuclear number from baseline versus time (hours), calculated in 690 
GraphPad Prism (GraphPad Software, USA). 691 
Gene knockdown in human hepatic stellate cells 692 
Knockdown of NOTCH3 in human HSC was performed using siRNA. HSC were plated 693 
at 75,000 cells per well in a 12 well plate (Costar, 3513) followed by serum starvation 694 
overnight (in HSC medium without FBS). siRNA duplexes with Lipofectamine 695 
RNAiMAX Transfection Reagent (ThermoFisher, 13778075) were prepared in 696 
OptiMEM (ThermoFisher, 31985070) according to the manufacturer’s 697 
recommendations, and used at a concentration of 50nM. Cells were exposed to the 698 
duplex for 48 hours, in HSC media containing 2% FBS. Cells were harvested for RNA 699 
and RT-qPCR. Knockdown efficiency was assessed by NOTCH3 RT-qPCR. The best 700 
siRNA for knockdown was determined empirically using the FlexiTube GeneSolution 701 
kit (Qiagen, GS4854). HSC treated with control siRNA (Qiagen, 1027280) and siRNA 702 
for NOTCH3 (Qiagen, Hs_NOTCH3_3, SI00009513; knockdown 83%) were then 703 
assessed for fibrillar collagen gene expression. 704 




Primary murine HSC culture were isolated from healthy mice as described80. Briefly, 706 
after cannulation of the inferior vena cava, the portal vein was cut to allow retrograde 707 
step-wise perfusion with pronase (Sigma, P5147) and collagenase D (Roche, 708 
11088882001) containing solutions, before ex vivo digestion in a solution containing 709 
pronase, collagenase D and Dnase1 (Roche, 10104159001). HSC were isolated from 710 
the digest solution by Histodenz (Sigma, D2158-100G) gradient centrifugation. HSC 711 
were plated at a density of 400,000 cells per well in a 24 well plate (Costar, 3524) in 712 
HSC media containing 10% FBS. Following overnight culture, cells were washed with 713 
PBS and cultured in HSC media containing 2% FBS. For macrophage co-culture, 714 
transwell inserts (0.4μm polyester membrane; Costar, 3470) were then placed above 715 
adherent HSC. FACS-sorted CD9+ mSAM or CD9- mTMo from CCl4-treated mice 716 
were resuspended in HSC media containing 2% FBS at 400,000 cells/ml and 200,000 717 
cells added to the top of the transwell insert. Co-culture proceeded for 48 hours and 718 
HSC were harvested for RNA. Quiescent HSC (harvested at start of co-culture) were 719 
used as a control population. 720 
Human liver endothelial cell isolation 721 
Human liver endothelial cells (LEC) were isolated from cirrhotic explant livers and 722 
non-fibrotic control donor liver as previously described81. Endothelial cells were 723 
cultured on plasticware coated with rat-tail collagen (Sigma, C3867) in complete LEC 724 
medium consisting of endothelial basal media (ThermoFisher, 11111044) containing 725 
10% heat inactivated human serum (tcsBiosciences, CS100-500), 100U penicillin, 100 726 
µg/mL streptomycin, 2mM glutamine (Sigma, G6784), VEGF (10 ng/mL; Peprotech, 727 
100-20) and 10 ng/mL HGF (10 ng/mL; Peprotech, 100-39). LEC expression of 728 
PLVAP, CD34, ACKR1 and JAG1 was assessed using flow cytometry. 729 
Flow-based adhesion assays 730 
Flow-based adhesion assays were performed as described56,81. Briefly, LEC from 731 
healthy and cirrhotic liver were seeded into a rat-tail collagen coated Ibidi slide VI0.4 732 
(Ibidi, 80606) at a density to give a monolayer and incubated overnight. Peripheral 733 
blood was collected from healthy donors in EDTA-coated tubes. Peripheral blood 734 
monocuclear cells (PBMC) were isolated using a lympholyte density gradient 735 




0.15% bovine serum albumin (PBS/BSA). Monocytes were enriched from PBMC using 737 
pan-monocyte isolation kit (Miltenyi biotech, 130-096-537) according the 738 
manufacturer’s protocol. For flow-based adhesion assay, cells were resuspended at 106 739 
cells per millilitre in endothelial basal media (ThermoFisher, 11111044) containing 740 
0.15% BSA, then perfused over the LEC monolayer for 5min at 0.28ml/min. Non-741 
adherent cells were washed off during 5min perfusion of 0.15% BSA human basal 742 
endothelial medium and 10 random non-overlapping images were randomly recorded 743 
from each channel. Total adherent (bright-phase; expressed as cell number/mm2/1 744 
million cells perfused) and transmigrating cells  (dark-phase; expressed as percentage 745 
total adherent cells) on an LEC monolayer from each patient were counted and 746 
quantified as previously described56. 747 
Gene knockdown in endothelial cells 748 
Knockdown of ACKR1 and PLVAP gene expression in human cirrhotic LEC was 749 
performed using siRNA as previously described81. In brief, siRNA duplexes for 750 
PLVAP, ACKR1, or negative control (Qiagen, 1027280) with Lipofectamine 751 
RNAiMAX Transfection Reagent (ThermoFisher, 13778075) were prepared in 752 
OptiMEM (ThermoFisher, 31985070) according to the manufacturer’s 753 
recommendations, and used at a concentration of 25nM. Cells were exposed to the 754 
duplex for 4 hours at 37oC after which time the media was replaced with endothelial 755 
basal media containing 10% heat-inactivated human serum for 24 hours. The media 756 
was then replaced with complete LEC media and incubated at 37oC with 5% CO2 for a 757 
further 24 hours. Knockdown efficacy was assessed by flow cytometry and mean 758 
fluorescence intensity (Extended Data Fig. 8f). The best siRNA for knockdown was 759 
determined empirically using the FlexiTube GeneSolution kit (Qiagen, GS83483 760 
(PLVAP) and GS2532 (ACKR1)). For flow-based adhesion assays, siRNAs for 761 
PLVAP (Qiagen, Hs_PLVAP_1, SI00687547; knockdown 50.6%, ACKR1 (Qiagen, 762 
Hs_Fy_5, SI02627667; knockdown 37.7%) or control siRNA were selected.  90,000 763 
LEC from cirrhotic patients (n=6) were seeded into channels of a rat-tail collagen 764 
coated Ibidi slide VI0.4, gene knockdown performed, followed by flow-based adhesion 765 
assay as described above. 766 




HSC (15,000 cells) were seeded into an Ibidi slide VI0.4 with and without primary 768 
human LEC (15,000 cells) from individual cirrhotic patients (n=3) in LEC complete 769 
medium. After 2h, all growth factor supplements were removed and cells were cultured 770 
for a further 72 hours in endothelial basal media containing 10% heat-inactivated 771 
human serum ± Notch-signalling inhibitor Dibenzazepine (Bio-Techne, 4489/10) or 772 
vehicle (DMSO) control.  Cells were fixed in 4% PFA for 30 minutes, permeabilised 773 
with 0.3% Triton PBS for 5 minutes, blocked with 10% goat serum in PBS for 30 774 
minutes followed by primary antibody incubation (mouse anti-PECAM1 and rabbit 775 
anti-collagen 1; see Supplementary table 18) for 1 hour. Cells were washed in 0.1% 776 
Triton PBS followed by addition of fluorescently-conjugated secondary antibodies 777 
(1:500 dilution) for 1 hour. Cells were mounted with Pro-long Gold anti-fade DAPI, 778 
images were taken on the Confocal Microscope Zeiss LSM780, and collagen 1 area 779 
staining quantified using IMARIS. 780 
RNA extraction and RT-qPCR 781 
RNA was isolated from HSC using the RNeasy Plus Micro Kit (Qiagen, 74034) and 782 
cDNA synthesis performed using QuantiTect Reverse Transcription Kit (Qiagen, 783 
205313) according to the manufacturer’s protocol. Reactions were performed in 784 
triplicate in 384-well plate format and were assembled using the QIAgility automated 785 
pipetting system (Qiagen). RT-qPCR for human HSC was performed using PowerUp 786 
SYBR Green Master Mix (ThermoFisher, A25777) with the following primers (all 787 
Qiagen): GAPDH (QT00079247), COL1A1 (QT00037793), COL3A1 (QT00058233), 788 
NOTCH3 (QT00003374). RT-qPCR for mouse HSC was performed using TaqMan 789 
Fast Advanced Master Mix (ThermoFisher, 4444557) with the following primers: 790 
Gapdh (ThermoFisher, Mm99999915_g1) and Col3a1 (ThermoFisher, 791 
Mm00802300_m1). Samples were amplified on an ABI 7900HT FAST PCR system 792 
(Applied Biosystems, ThermoFisher Scientific). Data was analysed using 793 
ThermoFisher Connect cloud qPCR analysis software (ThermoFisher Scientific). The 794 
2−ΔΔCt  quantification method, using GAPDH for normalization, was used to estimate 795 
the amount of target mRNA in samples, and expression calculated relative to average 796 




Immunohistochemistry, immunofluorescence, smFISH 798 
Formalin-fixed paraffin-embedded human liver tissue was cut into 4 μm sections, 799 
dewaxed, rehydrated, then incubated in 4% neutral-buffered formalin for 20 minutes. 800 
Following heat-mediated antigen retrieval in pH6 sodium citrate (microwave; 15 801 
minutes), slides were washed in PBS and incubated in 4% hydrogen peroxide for 10 802 
minutes. Slides were then washed in PBS, blocked using protein block (GeneTex, 803 
GTX30963) for 1 hour at room temperature before incubation with primary antibodies 804 
for 1 hour at room temperature. A full list of primary antibodies and conditions are 805 
shown in Supplementary Table 18.  Slides were washed in PBST (PBS plus 0.1% 806 
Tween20; Sigma-Aldrich, P1379) then incubated with ImmPress HRP Polymer 807 
Detection Reagents (depending on species of primary; rabbit, MP-7401; mouse, MP-808 
6402-15; goat, MP-7405; all Vector Laboratories) for 30 minutes at room temperature. 809 
Slides were washed in PBS followed by detection. For DAB staining, sections were 810 
incubated with DAB (DAKO, K3468) for 5 minutes and washed in PBS before a 811 
haematoxylin (Vector Laboratories, H3404) counterstain. For multiplex 812 
immunofluorescence staining, following the incubation with ImmPress and PBS wash, 813 
initial staining was detected using either Cy3, Cy5, or Fluorescein tyramide (Perkin-814 
Elmer, NEL741B001KT) at a 1:1000 dilution. Slides were then washed in PBST 815 
followed by further heat treatment with pH6 sodium citrate (15 minutes), washes in 816 
PBS, protein block, incubation with the second primary antibody (incubated overnight 817 
at 4oC), ImmPress Polymer and tyramide as before. This sequence was repeated for the 818 
third primary antibody (incubated at room temperature for 1 hour) and a DAPI-819 
containing mountant was then applied (ThermoFisher Scientific, P36931). All 820 
immunofluorescence stains were repeated in a minimum of 3 patients and 821 
representative images are displayed. 822 
For AMEC Staining (only CLEC4M immunohistochemistry), all washes were carried 823 
out with TBST (dH2O, 2oomM Tris, 1.5M NaCl, 1% Tween20 (all Sigma-Aldrich) 824 
pH7.5) and peroxidase blocking was carried out for 30mins in 0.6% hydrogen peroxide 825 
in Methanol. Sections were incubated with AMEC (Vector Laboratories, SK-4285) for 826 
20 minutes and washed in TBST (dH2O, 200mM Tris, 1.5M NaCl, 1% Tween20 (all 827 




For combined single-molecule fluorescent in situ hybridization (smFISH) and 829 
immunofluorescence, detection of TREM2 was performed using the RNAscope® 2.5 830 
LS Reagent Kit - BrownAssay (Advanced Cell Diagnostics (ACD)) in accordance with 831 
the manufacturer’s instructions. Briefly, 5 μm tissue sections were dewaxed, incubated 832 
with endogenous enzyme block, boiled in pretreatment buffer and treated with protease, 833 
followed by target probe hybridization using the RNAscope® LS 2.5 Hs-TREM2 834 
(420498, ACD) probe. Target RNA was then detected with Cy3 tyramide (Perkin-835 
Elmer, NEL744B001KT) at 1:1000 dilution. The sections were then processed through 836 
a pH6 sodium citrate heat-mediated antigen retrieval, hydrogen peroxidase treatment 837 
and protein block (all as for multiplex immunofluorescence staining as above). MNDA 838 
antibody was applied overnight at 4oC, completed using a secondary ImmPress HRP 839 
Anti-Rabbit Peroxidase IgG (Vector Laboratories, MP7401), visualised using a 840 
Flourescein tyramide (Perkin-Elmer, NEL741B001KT) at a 1:1000 dilution and stained 841 
with DAPI. 842 
Brightfield and fluorescently-stained sections were imaged using the slide scanner 843 
AxioScan.Z1 (Zeiss) at 20X magnification (40X magnification for smFISH). Images 844 
were processed and scale bars added using Zen Blue (Zeiss) and Fiji software82.  845 
Cell counting and image analysis  846 
Automated cell counting was performed using QuPath software83. Briefly, DAB-847 
stained whole tissue section slide-scanned images (CZI files) were imported into 848 
QuPath. Cell counts were carried out using the positive cell detection tool, detecting 849 
haematoxylin-stained nuclei and then thresholding for positively-stained DAB cells, 850 
generating DAB-positive cell counts/mm2 tissue. Identical settings and thresholds were 851 
applied to all slides for a given stain and experiment. For cell counts of fibrotic septae 852 
vs parenchymal nodules, the QuPath segmentation tool was used to segment the DAB-853 
stained whole tissue section into fibrotic septae or non-fibrotic parenchymal nodule 854 
regions using tissue morphological characteristics (Fig. 2j). Positive cell detection was 855 
then applied to the fibrotic and non-fibrotic regions in turn, providing cell DAB-positive 856 





Digital morphometric pixel analysis was performed using the Trainable Weka 859 
Segmentation (TWS) plugin84 in Fiji software82. Briefly, each stained whole tissue 860 
section slide-scanned image was converted into multiple TIFF files in Zen Blue 861 
software (Zeiss). TIFF files were imported into Fiji and TWS plugin trained to produce 862 
a classifier which segments images into areas of positive staining, tissue background 863 
and white space84. The same trained classifier was then applied to all TIFF images from 864 
every tissue section for a particular stain, providing a percentage area of positive 865 
staining for each tissue section. For digital morphometric quantification of positive 866 
staining of fibrotic septae versus parenchymal nodules, TIFF images were segmented 867 
into fibrotic septae or non-fibrotic parenchymal nodule regions using tissue 868 
morphological characteristics, followed by analysis using the TWS plugin in Fiji 869 
software. 870 
Histological assessment of NASH sections 871 
Haematoxylin and eosin and picro-sirius red stained sections from each case were 872 
whole-slide imaged using a NanoZoomer imager (Hamamatsu Photonics, Japan). 873 
Images of stained sections were independently scored by a consultant liver transplant 874 
histopathologist (T.J.K.) at the national liver transplant centre with experience in trial 875 
scoring by applying the ordinal NAFLD activity score85. For observer-independent 876 
quantification of picro-sirius red positive staining, images were split using ndpisplit86 877 
into tiles of x5 magnification before the application of a classifier that had been trained 878 
by the liver histopathologist using the machine learning WEKA plugin in FIJI82,84, as 879 
previously described87. All analysis was undertaken blind to all other data. 880 
Droplet-based scRNA-seq 881 
Single cells were processed through the Chromiumä Single Cell Platform using the 882 
Chromiumä Single Cell 3’ Library and Gel Bead Kit v2 (10X Genomics, PN-120237) 883 
and the Chromiumä Single Cell A Chip Kit (10X Genomics, PN-120236) as per the 884 
manufacturer’s protocol. In brief, single cells were sorted into PBS + 0.1% BSA, 885 
washed twice and counted using a Bio-Rad TC20. 10,769 cells were added to each lane 886 




Chromiumä instrument, where cell lysis and barcoded reverse transcription of RNA 888 
occurred, followed by amplification, fragmentation and 5′ adaptor and sample index 889 
attachment. Libraries were sequenced on an Illumina HiSeq 4000. 890 
Computational Analysis 891 
Pre-processing scRNA-seq data  892 
We aligned to the GRCh38 and mm10 (Ensembl 84) reference genomes as appropriate 893 
for the input dataset, and estimated cell-containing partitions and associated UMIs, 894 
using the Cell Ranger v2.1.0 Single-Cell Software Suite from 10X Genomics. Genes 895 
expressed in fewer than three cells in a sample were excluded, as were cells that 896 
expressed fewer than 300 genes or mitochondrial gene content >30% of the total UMI 897 
count. We normalised by dividing the UMI count per gene by the total UMI count in 898 
the corresponding cell and log-transforming. Variation in UMI counts between cells 899 
was regressed according to a negative binomial model, prior to scaling and centering 900 
the resulting value by subtracting the mean expression of each gene and dividing by its 901 
standard deviation (En), then calculating ln(104*En+1). 902 
Dimensionality reduction, clustering, and DE analysis 903 
We performed unsupervised clustering and differential gene expression analyses in the 904 
Seurat R package v2.3.088. In particular we used SNN graph-based clustering, where 905 
the SNN graph was constructed using from 2 to 11 principal components as determined 906 
by dataset variability shown in principal components analysis (PCA); the resolution 907 
parameter to determine the resulting number of clusters was also tuned accordingly. To 908 
assess cluster similarity we used the BuildClusterTree function from Seurat. 909 
In total, we present scRNA-seq data from ten human liver samples (named Healthy 1-910 
5 and Cirrhotic 1-5), five human blood samples (n=4 cirrhotic named Blood 1-4 and 911 
n=1 healthy named PBMC8K; pbmc8k dataset sourced from single-cell gene 912 
expression datasets hosted by 10X Genomics), and two mouse liver samples (n=3 913 
uninjured and n=3 fibrotic). For seven human liver samples (Healthy 1-4 and Cirrhotic 914 
1-3) we performed scRNA-seq on both leucocytes (CD45+) and other non-parenchymal 915 
cells (CD45-); for the remaining three human livers (Healthy 5, Cirrhotic 4-5) we 916 




Initially, we combined all human scRNA-seq datasets (liver and blood) and performed 918 
clustering analysis with the aim of isolating a population of liver-resident cells, by 919 
identifying contaminating circulatory cells within datasets generated from liver digests 920 
and removing them from downstream analysis. Specifically, we removed from our liver 921 
datasets cells that fell into clusters 1 and 13 of the initial dataset in Extended Data Fig. 922 
1d. 923 
Using further clustering followed by signature analysis, we interrogated this post-924 
processed liver-resident cell dataset for robust cell lineages. These lineages were 925 
isolated into individual datasets, and the process was iterated to identify robust lineage 926 
subpopulations. At each stage of this process we removed clusters expressing more than 927 
one unique lineage signature in more than 25% of their cells from the dataset as 928 
probable doublets. Where the cell proliferation signature identified distinct cycling 929 
subpopulations, we re-clustered these again to ascertain the identity of their constituent 930 
cells. 931 
The murine scRNA-seq datasets were combined, clustered, and interrogated for cell 932 
lineages in a similar manner as their human counterparts. 933 
All heatmaps, t-SNE and UMAP visualisations, violin plots, and dot plots were 934 
produced using Seurat functions in conjunction with the ggplot2, pheatmap, and grid 935 
R packages. t-SNE and UMAP visualisations were constructed using the same number 936 
of principal components as the associated clustering, with perplexity ranging from 30 937 
to 300 according to the number of cells in the dataset or lineage. We conducted 938 
differential gene expression analysis in Seurat using the standard AUC classifier to 939 
assess significance. We retained only those genes with a log-fold change of at least 0.25 940 
and expression in at least 25% of cells in the cluster under comparison. 941 
Defining cell lineage signatures 942 
For each cell we obtained a signature score across a curated list of known marker genes 943 
per cell lineage in the liver (Supplementary Table 1). This signature score was defined 944 
as the geometric mean of the expression of the associated signature genes in that cell. 945 




each cell with signature less than a given threshold (the mean of said signature score 947 
across the entire dataset) was set as 0. 948 
Batch effect and quality control 949 
To investigate agreement between samples we extracted the average expression profile 950 
for a given cell lineage in each sample, and calculated the Pearson correlation 951 
coefficients between all possible pairwise comparisons of samples per lineage89.  952 
Imputing dropout in T cell and ILC clusters 953 
To impute dropout of low-abundance transcripts in our T cell and ILC clusters so that 954 
we might associate them with known subpopulations, we down-sampled to 7,380 cells 955 
from 36,900 and applied the scImpute R package v0.0.890, using as input both our 956 
previous annotation labels and k-means spectral clustering (k=5), but otherwise default 957 
parameters. 958 
Analysing functional phenotypes of scar-associated cells 959 
For further analysis of function we adopted the self-organising maps (SOM) approach 960 
as implemented in the SCRAT R package v1.0.091. For each lineage of interest we 961 
constructed a SOM in SCRAT using default input parameters and according to its 962 
clusters. We defined the signatures expressed in a cell by applying a threshold criterion 963 
(ethresh = 0.95 × emax) selecting the highest-expressed metagenes in each cell, and 964 
identified for further analysis those metagene signatures defining at least 30% of cells 965 
in at least one cluster within the lineage. We smoothed these SOMs using the 966 
disaggregate function from the raster R package for visualisation purposes, and scaled 967 
radar plots to maximum proportional expression of the signature. Gene ontology 968 
enrichment analysis on the genes in these spots was performed using PANTHER 13.1 969 
(pantherdb.org). 970 
Inferring injury dynamics and transcriptional regulation 971 
To generate cellular trajectories (pseudotemporal dynamics) we used the monocle R 972 
package v2.6.192. We ordered cells in a semi-supervised manner based on their Seurat 973 
clustering, scaled the resulting pseudotime values from 0 to 1, and mapped them onto 974 
either the t-SNE or UMAP visualisations generated by Seurat or diffusion maps as 975 




We removed mitochondrial and ribosomal genes from the geneset for the purposes of 977 
trajectory analysis. Differentially-expressed genes along this trajectory were identified 978 
using generalised linear models via the differentialGeneTest function in monocle. 979 
When determining significance for differential gene expression along the trajectory, we 980 
set a q-value threshold of 1e-20. We clustered these genes using hierarchical clustering 981 
in pheatmap, cutting the tree at k=3 to obtain gene modules with correlated gene 982 
expression across pseudotime. Cubic smoothing spline curves were fitted to scaled gene 983 
expression along this trajectory using the smooth.spline command from the stats R 984 
package, and gene ontology enrichment analysis again performed using PANTHER 985 
13.1. 986 
We verified the trajectory and its directionality using the velocyto R package v0.6.034, 987 
estimating cell velocities from their spliced and unspliced mRNA content. We 988 
generated annotated spliced and unspliced reads from the 10X BAM files via the 989 
dropEst pipeline, before calculating gene-relative velocity using kNN pooling with 990 
k=25, determining slope gamma with the entire range of cellular expression, and fitting 991 
gene offsets using spanning reads. Aggregate velocity fields (using Gaussian smoothing 992 
on a regular grid) and transition probabilities per lineage subpopulations were 993 
visualised on t-SNE, UMAP, or diffusion map visualisations as generated previously. 994 
Gene-specific phase portraits were plotted by calculating spliced and unspliced mRNA 995 
levels against steady-state inferred by a linear model; levels of unspliced mRNA above 996 
and below this steady-state indicate increasing and decreasing expression of said gene, 997 
respectively. Similarly we plotted unspliced count signal residual per gene, based on 998 
the estimated gamma fit, with positive and negative residuals indicating expected 999 
upregulation and downregulation respectively. 1000 
For transcription factor analysis, we obtained a list of all genes identified as acting as 1001 
transcription factors in humans from AnimalTFDB94. To further analyse transcription 1002 
factor regulons, we adopted the SCENIC v0.1.7 workflow in R95, using default 1003 
parameters and the normalised data matrices from Seurat as input. For visualisation, we 1004 
mapped the regulon activity (AUC) scores thus generated to the pseudotemporal 1005 




Analysing inter-lineage interactions within the fibrotic niche 1007 
For comprehensive systematic analysis of inter-lineage interactions within the fibrotic 1008 
niche we used CellPhoneDB69. CellPhoneDB is a manually curated repository of 1009 
ligands, receptors, and their interactions, integrated with a statistical framework for 1010 
inferring cell-cell communication networks from single-cell transcriptomic data. In 1011 
brief, we derived potential ligand-receptor interactions based on expression of a 1012 
receptor by one lineage subpopulation and a ligand by another; as input to this algorithm 1013 
we used cells from the fibrotic niche as well as liver sinusoidal endothelial cells and 1014 
Kupffer cells as control, and we considered only ligands and receptors expressed in 1015 
greater than 5% of the cells in any given subpopulation. Subpopulation-specific 1016 
interactions were identified as follows: 1) randomly permuting the cluster labels of all 1017 
cells 1000 times and determining the mean of the average receptor expression of a 1018 
subpopulation and the average ligand expression of the interacting subpopulation, thus 1019 
generating a null distribution for each ligand-receptor pair in each pairwise comparison 1020 
between subpopulations, 2) calculating the proportion of these means that were "as or 1021 
more extreme" than the actual mean, thus obtaining a p-value for the likelihood of 1022 
subpopulation specificity for a given ligand-receptor pair, 3) prioritising interactions 1023 
that displayed specificity to subpopulations interacting within the fibrotic niche. 1024 
Canonical correlation analysis 1025 
To compare human and murine populations of monocytic phagocytes, we used 1026 
canonical correlation analysis as implemented in Seurat39. We map the genes in the 1027 
human dataset to their murine orthologues using biomaRt, discarding any genes for 1028 
which no orthologues can be found. We then calculate the shared low-dimensional 1029 
subspace on the union of genes that are variably expressed in both datasets (n=159), 1030 
and align using six canonical components as determined by evaluating the biweight 1031 
midcorrelation. Results are visualised on t-SNEs as previously described. 1032 
Deconvolution of whole liver microarray data 1033 
To assess macrophage composition early-stage NAFLD, we performed deconvolution 1034 
analysis on publicly available microarray data from annotated liver biopsy specimens 1035 
taken across the NAFLD disease spectrum (GEO accession GSE48452)47. Tissue MP 1036 




MP populations. Signature gene expression profiles of SAM, TMo, KC were used to 1038 
deconvolve the monocyte-macrophage composition of liver biopsy samples from 1039 
GSE48452 using Cibersort96, as previously described46. The monocyte-macrophage 1040 
composition of each biopsy sample was then compared to the associated histological 1041 
and demographic features, available from the GEO database. 1042 
Statistical Analysis 1043 
To assess whether our identified subpopulations were significantly overexpressed in 1044 
injury, we posited the proportion of injured cells in each cluster as a random count 1045 
variable using a Poisson process, as previously described89. We modelled the rate of 1046 
detection using the total number of cells in the lineage profiled in a given sample as an 1047 
offset, with the condition of each sample (healthy vs cirrhotic) provided as a covariate 1048 
factor. The model was fitted using the R command glm from the stats package. The p-1049 
value for the significance of the proportion of injured cells was assessed using a Wald 1050 
test on the regression coefficient. This methodology was also applied to assess 1051 
significant changes in proportions of mononuclear phagocytes between healthy and 1052 
cirrhotic liver tissue by flow cytometry. 1053 
Remaining statistical analyses were performed using GraphPad Prism (GraphPad 1054 
Software, USA). Comparison of changes between two groups was performed using a 1055 
Mann-Whitney test (unpaired; two-tailed) or using a Wilcoxon matched-pairs signed 1056 
rank test (paired; two-tailed). Comparison of changes between multiple groups was 1057 
performed using a Kruskal-Wallis and Dunn, one-way ANOVA and Tukey or repeated 1058 
measures one-way ANOVA and Tukey tests. Correlations were preformed using 1059 
Pearson correlation and best fit line plotted using linear regression. P-values<0.05 were 1060 
considered statistically significant. 1061 
Data and materials availability 1062 
Our expression data will be freely available for user-friendly interactive browsing 1063 
online at http://www.livercellatlas.mvm.ed.ac.uk (log-in details for purposes of review; 1064 
username: Edinburghlivercellatlas; password: Cirrhosis). CellPhoneDB is available at 1065 




and heteromeric complexes. All raw sequencing data will be deposited in the Gene 1067 
Expression Omnibus (GEO; GEO NO. XXXX). 1068 
Code availability 1069 
R scripts enabling the main steps of the analysis are available from the corresponding 1070 
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Figure 1: Single cell atlas of human liver non-parenchymal cells. 1369 
a, Overview: extraction of non-parenchymal cells (NPC) from healthy or cirrhotic 1370 
human liver, followed by fluorescence-activated cell sorting (FACS) into leucocyte 1371 
(CD45+) and other NPC fractions (CD45-) for droplet-based 3' single-cell RNA-seq. b, 1372 
t-SNE visualisation: clustering (colour) 66,135 non-parenchymal cells (points; n=5 1373 
healthy and n=5 cirrhotic human livers). c, t-SNE visualisation: injury condition 1374 
(colour; healthy versus cirrhotic). d, t-SNE visualisation: cell lineage (colour) inferred 1375 
from expression of known marker gene signatures. Endo, endothelial cell; ILC, innate 1376 
lymphoid cell; Mast, mast cell; Mes, mesenchymal cell; MP, mononuclear phagocyte; 1377 
pDC, plasmacytoid dendritic cell. e, Scaled heatmap (red, high; blue, low): cluster 1378 
marker genes (top, colour coded and numbered by cluster and colour coded by 1379 
condition) and exemplar genes and lineage annotation labelled (right). Cells columns, 1380 
genes rows.  1381 
FACS
Leucocytes (CD45+)



































































































































































































Figure 2: Identifying scar-associated macrophage subpopulations. 1382 
a, t-SNE visualisation: clustering 10,737 mononuclear phagocytes (MP) into 10 clusters 1383 
(colour and number). Annotation of clusters (identity). TMo, tissue monocyte; SAM, 1384 
scar-associated macrophage; KC, Kupffer cell; cDC, conventional dendritic cell. b, t-1385 
SNE visualisation: annotating MP cells by injury condition (colour). c, Fractions of MP 1386 
subpopulations in healthy (n=5) versus cirrhotic (n=5) livers, Wald test. d, Scaled 1387 
heatmap (red, high; blue, low): MP cluster marker genes (top, colour coded by cluster 1388 
and condition), exemplar genes labelled (right). Cells columns, genes rows. e, Violin 1389 
plots: scar-associated macrophage and tissue monocyte cluster markers. f, 1390 
Representative flow cytometry plots: quantifying TREM2+CD9+ MP fraction by flow 1391 
cytometry in healthy (n=2) versus cirrhotic (n=3) liver, Wald. g, Representative 1392 
immunofluorescence micrograph, cirrhotic liver: TREM2 (red), CD9 (white), collagen 1393 
1 (green), DAPI (blue). Scale bar, 50μm. h, Automated cell counting: TREM2 staining, 1394 
healthy (n=10) versus cirrhotic (n=9) liver, Mann-Whitney. i, Automated cell counting: 1395 
CD9 staining, healthy (n=12) versus cirrhotic (n=10) liver, Mann-Whitney. j, 1396 
Topographically assessing scar-associated macrophages: exemplar tissue segmentation 1397 
(left), stained section morphologically segmented into fibrotic septae (orange) and 1398 
parenchymal nodules (purple)). TREM2+, CD9+, TIMD4+ and MARCO+ automated 1399 
cell counts (right) in parenchymal nodules versus fibrotic septae, Wilcoxon. Error bars, 1400 





























































































































































































































































































































Figure 3: Fibrogenic phenotype of scar-associated macrophages. 1402 
a, Self-Organising Map (SOM; 60x60 grid): smoothed scaled metagene expression of 1403 
mononuclear phagocyte (MP) lineage. 20,952 genes, 3,600 metagenes, 44 signatures. 1404 
A-F label metagene signatures overexpressed in one or more MP subpopulations. b, 1405 
Radar plots (left): metagene signatures A-C showing distribution of signature 1406 
expression across MP subpopulations, exemplar genes (middle) and Gene Ontology 1407 
(GO) enrichment (right). c, Diffusion map visualisation, blood monocytes and liver-1408 
resident MP lineages (23,075 cells), annotating monocle pseudotemporal dynamics 1409 
(purple to yellow). RNA velocity field (red arrows) visualised using Gaussian 1410 
smoothing on regular grid. Below: Annotation of MP subpopulation, injury condition. 1411 
d, UMAP visualisation, blood monocytes and liver-resident MP lineages, annotating 1412 
monocle pseudotemporal dynamics (purple to yellow). RNA velocity field (red arrows) 1413 
visualised using Gaussian smoothing on regular grid. Below: Annotation of MP 1414 
subpopulation, injury condition. e, Unspliced-spliced phase portraits (top row), cells 1415 
coloured as in d, for monocyte (MNDA), SAM (CD9) and KC marker genes (TIMD4). 1416 
Cells plotted above or below the steady-state (black dashed line) indicate increasing or 1417 
decreasing expression of gene, respectively. Spliced expression profile for genes 1418 
(middle row; red high, blue low). Unspliced residuals (bottom row), positive (red) 1419 
indicating expected upregulation, negative (blue) indicating expected downregulation 1420 
for genes. MNDA displays negative velocity in SAM, CD9 displays positive velocity in 1421 
monocytes and SAM, TIMD4 velocity is restricted to KC. f, UMAP visualisation, 1422 
transition probabilities per SAM subpopulation, indicating for each cell the likelihood 1423 
of transition into either SAM(1) or SAM(2), calculated using RNA velocity (yellow 1424 
high; purple low; grey below threshold of 2x10-4). g, Scaled heatmap (red, high; blue 1425 
low): cubic smoothing spline curves fitted to genes differentially expressed across 1426 
blood monocyte-to-SAM (right arrow) and blood monocyte-to-cDC (left arrow) 1427 
pseudotemporal trajectories, grouped by hierarchical clustering (k=3). Gene co-1428 
expression modules (colour) labelled right. h, Cubic smoothing spline curve fitted to 1429 
averaged expression of all genes in module 1, along monocyte-SAM pseudotemporal 1430 
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Figure 4: Identifying scar-associated endothelial subpopulations. 1432 
a, t-SNE visualisation: clustering 8,020 endothelial cells, annotating injury condition. 1433 
b, Fractions of endothelial subpopulations in healthy (n=4) versus cirrhotic (n=3) livers, 1434 
Wald. c, Scaled heatmap (red, high; blue, low): endothelial cluster marker genes (colour 1435 
coded top by cluster and condition), exemplar genes labelled right. Cells columns, 1436 
genes rows. d, Representative immunofluorescence micrograph, healthy versus 1437 
cirrhotic liver: CD34 (red), CLEC4M (white), PLVAP (green), DAPI (blue). e, 1438 
Representative immunofluorescence micrographs, healthy versus cirrhotic liver: 1439 
RSPO3, PDPN, AIF1L, VWA1 or ACKR1 (red), CD34 (white), PLVAP (green), DAPI 1440 
(blue).  f, Digital morphometric pixel quantification: CLEC4M staining healthy (n=5) 1441 
versus cirrhotic (n=8), PLVAP staining healthy (n=11) versus cirrhotic (n=11), ACKR1 1442 
staining healthy (n=10) versus cirrhotic (n=10), Mann-Whitney. g, Scaled heatmap 1443 
(red, high; blue, low): endothelial cluster marker transcription factor regulons (colour 1444 
coded top by cluster and condition), exemplar regulons labelled right. Cells in columns, 1445 
regulons in rows. Scale bars, 50μm. Error bars, s.e.m.; * p-value < 0.05, ** p-value < 1446 


















































































































































































































Figure 5: Identifying scar-associated mesenchymal cell populations. 1448 
a, t-SNE visualisation: clustering 2,318 mesenchymal cells (Mes) into 4 clusters (colour 1449 
and number). Annotation of clusters (identity). VSMC, vascular smooth muscle cell; 1450 
HSC, hepatic stellate cell; SAMes, scar-associated mesenchymal cell. Annotation by 1451 
injury condition (colour). b, Scaled heatmap (red, high; blue, low): Mes cluster marker 1452 
genes (top, colour coded by cluster and condition), exemplar genes labelled (right). 1453 
Cells columns, genes rows. c, Representative immunofluorescence micrograph, healthy 1454 
versus cirrhotic liver: RGS5 (red), MYH11 (white), PDGFRα (green), DAPI (blue). d, 1455 
Violin plots: fibrillar collagen expression in mesenchymal cell clusters. e, Fractions of 1456 
mesenchymal subpopulations in healthy (n=4) versus cirrhotic (n=3) livers, Wald. f, 1457 
Digital morphometric pixel quantification: PDGFRα staining, healthy (n=11) versus 1458 
cirrhotic (n=11) liver (top), Mann-Whitney. Topographically assessing PDGFRα 1459 
staining, stained cirrhotic sections (n=10) morphologically segmented into fibrotic 1460 
septae and parenchymal nodules (bottom), Wilcoxon. Scale bars, 50μm. Error bars, 1461 




















































































































































Figure 6: Multi-lineage interactions in the fibrotic niche. 1463 
a to b, Representative immunofluorescence micrographs, fibrotic niche. a, TREM2 1464 
(red), PLVAP (white), PDGFRα (green), DAPI (blue). b, TREM2 (red), ACKR1 1465 
(white), PDGFRα (green), DAPI (blue). c, Dotplot: ligand-receptor interactions 1466 
between scar-associated macrophages (SAM) and scar-associated mesenchyme 1467 
(SAMes). X-axis, ligand (red) and cognate receptor (blue); y-axis, cell populations 1468 
expressing ligand (red) and receptor (blue); circle size, p-value; colour (red, high; 1469 
yellow, low), means of average ligand and receptor expression levels in interacting 1470 
subpopulations. d to e, Representative immunofluorescence micrographs, fibrotic 1471 
niche. d, TREM2 (red), PDGFB (white), PDGFRα (green), DAPI (blue), arrows 1472 
TREM2+PDGFB+ cells. e, TNFRSF12A (red), TNFSF12 (white), PDGFRα (green), 1473 
DAPI (blue), arrows TNFRSF12A+PDGFRα+ cells. f to h, Hepatic stellate cell (HSC) 1474 
proliferation assay: y-axis, area under curve (AUC) of % change in HSC number over 1475 
time (hours), one-way ANOVA and Tukey. f, Vehicle, PDGF-BB (10ng/ml), 1476 
Crenolanib (1μM), all n=3. g, Control, TNFSF12 (100ng/ml), anti-TNFRSF12A 1477 
(2μg/ml), isotype control (2μg/ml), all n=3. h, Conditioned media from hepatic 1478 
macrophages; SAM, tissue monocytes (TMo), Kupffer cells (KC), control, all n=2. i, 1479 
Dotplot: ligand-receptor interactions between scar-associated endothelial cells 1480 
(SAEndo) and SAMes. X-axis, ligand (red) and cognate receptor (blue); y-axis, cell 1481 
populations expressing ligand (red) and receptor (blue); circle size, p-value; colour (red, 1482 
high; yellow, low), means of average ligand and receptor expression levels in 1483 
interacting subpopulations. j, Endothelial cell JAG1 flow cytometry: healthy (n=3) or 1484 
cirrhotic (n=9) liver, representative histogram (top), mean fluorescence intensity (MFI, 1485 
bottom),  Mann-Whitney. k, Representative immunofluorescence micrographs, fibrotic 1486 
niche. NOTCH3 (red), DLL4 (white), PDGFRα (green), DAPI (blue), arrows 1487 
NOTCH3+PDGFRα+ cells. l to m, Cirrhotic endothelial cell and HSC co-culture, Notch 1488 
inhibitor Dibenzazepine (DBZ; 10μM). l, Representative immunofluorescence 1489 
micrographs, Collagen 1 (magenta), PECAM1 (green), DAPI (blue). m, Digital pixel 1490 
analysis; collagen 1 area, n=3 per condition, RM one-way ANOVA and Tukey. n, HSC 1491 
gene knockdown: control (n=7) or NOTCH3 (n=7) siRNA, qPCR of stated gene, 1492 
expression relative to mean expression of control siRNA, Mann-Whitney. Scale bars, 1493 
50μm. Error bars, s.e.m.; * p-value<0.05; ** p-value < 0.01; *** p-value < 0.001. 1494 
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Extended Data Figure 1: Strategy for isolation of human liver non-parenchymal 1495 
cells. 1496 
a, Patient demographics and clinical information. b, Representative flow cytometry 1497 
plots: gating strategy for isolating leucocytes (CD45+) and other non-parenchymal cells 1498 
(CD45-) from healthy and cirrhotic liver. c, Representative flow cytometry plots: gating 1499 
strategy for isolating peripheral blood mononuclear cells (PBMC). d, t-SNE 1500 
visualisation: clustering 103,568 cells (n=5 healthy human livers, n=5 cirrhotic human 1501 
livers, n=1 healthy PBMC, n=4 cirrhotic PBMC), annotating source (PBMC versus 1502 
liver) and cell lineage inferred from known marker gene signatures. Endo, endothelial 1503 
cell; ILC, innate lymphoid cell; Mast, mast cell; Mes, mesenchymal cell; MP, 1504 
mononuclear phagocyte; pDC, plasmacytoid dendritic cell. e, Dotplot: annotating 1505 
PBMC and liver dataset clusters by lineage signatures. Circle size indicates cell fraction 1506 
expressing signature greater than mean; colour indicates mean signature expression 1507 
(red, high; blue, low). f, Violin plots: number of unique genes (nGene) and number of 1508 
total Unique Molecular Identifiers (nUMI) expressed in PBMC. g, Pie charts: 1509 
proportion of cell lineage per PBMC sample. h, Box and whisker plot: agreement in 1510 
expression profiles across PBMC samples. Pearson correlation coefficients between 1511 
average expression profiles for cell in each lineage, across all pairs of samples. Black 1512 










































Age (yrs) 57.4±7.9 56.6±5.8 63.2±3.8
Gender (M:F) 4:1 3:2 3:1







Haemoglobin (g/l) 145±14 106±17 131±2.1
White Cell Count (x109/l) 8.2±2.2 5.9±1.7 3.7±1.5
Platelets (x109/l) 300±91 137±56 73±38
Prothrombin Time (s) 11.6±1.1 19.6±3.8 16.0±3.6
Creatinine (µmol/l) 76.4±14.5 96.8±28.6 74.5±9.7
Na+ (mmol/l) 141±2.6 131±7.0 139±2.1
Bilirubin (µmol/l) 10±5.2 79.6±83.5 36.3±20.0
ALT (IU/l) 27.8±19.3 77.8±80.7 96.2±121.0
ALP (IU/l) 122±47 140±80 203±153
MELD Score 6.6±0.5 17.3±4.5 11.7±4.3
NAFLD:Non-alcoholic fatty liver disease; ALD:Alcohol-related liver dsease; PBC:Primary 
biliary cholangitis; HH:Hereditary haemochromatosis; ALT:Alanine transaminase; 




























































































Pearson correlation between samples























































































Extended Data Figure 2: Quality control and annotation of human liver-resident 1514 
cells.  1515 
a, t-SNE visualisation: lineage signature expression across liver-resident cell dataset 1516 
(red, high; blue, low). b, Dotplot: annotating liver-resident cell clusters by lineage 1517 
signature. Circle size indicates cell fraction expressing signature greater than mean; 1518 
colour indicates mean signature expression (red, high; blue, low). c, Violin plot: number 1519 
of unique genes (nGene) expressed across liver-resident cell lineages in healthy versus 1520 
cirrhotic livers. d, Violin plot: number of total Unique Molecular Identifiers (nUMI) 1521 
expressed across liver-resident cell lineages in healthy versus cirrhotic livers. e, Pie 1522 
charts: proportion of cell lineage per liver sample. f, Box and whisker plot: agreement 1523 
in expression profiles across liver samples. Pearson correlation coefficients between 1524 
average expression profiles for cell in each lineage, across all pairs of samples. Black 1525 
bar, median value; box edges, 25th and 75th percentiles; whiskers, range. g, t-SNE 1526 
visualisation: liver-resident dataset per liver sample; Cirrhotic samples annotated by 1527 
aetiology of underlying liver disease; NAFLD, Non-alcoholic fatty liver disease; ALD, 1528 
Alcohol-related liver disease; PBC, Primary biliary cholangitis.  1529 
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Extended Data Figure 3: Annotating human liver lymphoid cells.  1530 
a, t-SNE visualisation: clustering 36,900 T cells and innate lymphoid cells (ILC), 1531 
annotating injury condition. cNK, cytotoxic NK cell. b, Fractions of T cell and ILC 1532 
subpopulations in healthy (n=5) versus cirrhotic (n=5) livers, Wald. c, t-SNE 1533 
visualisations: selected genes expressed in the T cell and ILC lineage. d, Scaled 1534 
heatmap (red, high; blue, low): T cell and ILC cluster marker genes (colour coded top 1535 
by cluster and condition), exemplar genes labelled right. Cells columns, genes rows. e, 1536 
t-SNE visualisations: downsampled T cell and ILC dataset (7,380 cells) pre- and post-1537 
imputation; annotating data used for visualisation and clustering, inferred lineage, 1538 
injury condition. No additional heterogeneity was observed following imputation. f, t-1539 
SNE visualisation: clustering 2,746 B cells and plasma cells, annotating injury 1540 
condition. g, Scaled heatmap (red, high; blue, low): B cell and plasma cell cluster 1541 
marker genes (colour coded top by cluster and condition), exemplar genes labelled 1542 
right. Cells columns, genes rows. h, Fractions of B cell and plasma cell subpopulations 1543 
in healthy (n=5) versus cirrhotic (n=5) livers, Wald. Error bars, s.e.m.; *** p-value < 1544 
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Extended Data Figure 4: Annotating human liver mononuclear phagocytes. 1546 
a, t-SNE visualisation: clustering and selected genes expressed in mononuclear 1547 
phagocyte (MP) lineage. b, Violin plots: Kupffer cell (KC) cluster markers. c, 1548 
Representative immunofluorescence micrograph, healthy versus cirrhotic liver: TIMD4 1549 
(red), CD163 (white), MARCO (green), DAPI (blue), arrows 1550 
CD163+MARCO+TIMD4- cells. d, Automated cell counting: TIMD4 staining, healthy 1551 
(n=12) versus cirrhotic (n=9) liver, Mann-Whitney. e, Automated cell counting: 1552 
MARCO staining, healthy (n=8) versus cirrhotic (n=8) liver, Mann-Whitney. f, 1553 
Representative flow cytometry plots: gating strategy for identifying KC, TMo and 1554 
SAM. SAM are detected as TREM2+CD9+ cells within the TMo and SAM gate (see 1555 
Fig. 2f). g, Representative immunofluorescence micrograph, cirrhotic liver: TREM2 1556 
(red), MNDA (white), collagen 1 (green), DAPI (blue). h, Representative micrograph, 1557 
cirrhotic liver: TREM2 (smFISH; red), MNDA (immunofluorescence; green), DAPI 1558 
(blue). i, Representative immunofluorescence micrograph, cirrhotic liver: CD9 (red), 1559 
MNDA (white), collagen 1 (green), DAPI (blue). j, Violin plots: cycling MP cluster 1560 
markers. k, Fractions of cycling MP subpopulations in healthy (n=5) versus cirrhotic 1561 
(n=5) livers, Wald. Scale bars, 50μm. Error bars, s.e.m.; * p-value < 0.05, *** p-value 1562 
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Extended Data Figure 5:  Phenotypic characterisation of mononuclear 1564 
phagocytes in healthy and cirrhotic human livers. 1565 
a, Self-Organising Map (SOM; 60x60 grid): smoothed mean metagene expression 1566 
profile for mononuclear phagocyte (MP) subpopulations. b, Radar plots (left): 1567 
metagene signatures D-F showing distribution of signature expression across MP 1568 
subpopulations, exemplar genes (middle) and Gene Ontology (GO) enrichment (right). 1569 
c, Luminex assay: quantification of levels of stated proteins in culture medium from 1570 
FACS-isolated scar-associated macrophages (SAM, n=3), tissue monocytes (TMo, 1571 
n=2), Kupffer cells (KC, n=2), and control (media alone, n=2). MFI, median 1572 
fluorescence intensity. d, Hepatic stellate cell (HSC) activation assay: HSC treated with 1573 
conditioned media from FACS-isolated SAM (n=3) or TMo (n=3); qPCR of stated 1574 
genes, expression relative to mean expression of control HSC (n=6), Kruskal-Wallis 1575 
and Dunn. e, Cubic smoothing spline curve fitted to averaged expression of all genes 1576 
in module 2 from blood monocyte-SAM pseudotemporal trajectory, selected GO 1577 
enrichment (right) and curves fit to exemplar genes (below). f, Cubic smoothing spline 1578 
curve fitted to averaged expression of all genes in module 3 from blood monocyte-cDC 1579 
pseudotemporal trajectory, GO enrichment (right) and curves fit to exemplar genes 1580 
(below). g, Scaled heatmap (red, high; blue, low): transcription factor regulons across 1581 
MP pseudotemporal trajectory and in KC. Colour coded top by MP cluster, condition 1582 
and pseudotime, selected regulons labelled right. Cells columns, regulons rows. h, 1583 
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Extended Data Figure 6: Characterisation of macrophages in mouse liver 1585 
fibrosis. 1586 
a, t-SNE visualisation: clustering 3,250 mouse mononuclear phagocytes (mMP) into 5 1587 
clusters (colour and number). Annotation of mouse clusters (identity). mTMo, tissue 1588 
monocyte; mSAM, scar-associated macrophage; mKC, Kupffer cell; mcDC, 1589 
conventional dendritic cell. b, t-SNE visualisation: annotating mMP cells by injury 1590 
condition (colour); healthy (uninjured) or fibrotic (4 weeks carbon tetrachloride 1591 
treatment). c, Scaled heatmap (red, high; blue, low): mMP cluster marker genes (top, 1592 
colour coded by cluster and condition), exemplar genes labelled (right). Cells columns, 1593 
genes rows. d, t-SNE visualisations: selected genes expressed in mMP. e, 1594 
Representative flow cytometry plots: gating strategy for identifying mKC, CD9- mTMo 1595 
and CD9+ mSAM. f, Quantifying mouse macrophage subpopulations by flow 1596 
cytometry: healthy (n=6) and fibrotic (n=8) mouse liver, macrophage subpopulation (x-1597 
axis) as a percentage of total viable CD45+ cells (y-axis), Mann-Whitney. g, Hepatic 1598 
stellate cell activation assay: co-culture of hepatic stellate cells (HSC) from uninjured 1599 
mouse liver and FACS-isolated macrophage subpopulations (Mθ) from fibrotic mouse 1600 
liver (left). Co-culture with CD9- mTMo (n=8) or CD9+ mSAM (n=8), qPCR of 1601 
Col3a1 in HSC, expression relative to mean expression of quiescent HSC (right), 1602 
Wilcoxon. h, t-SNE visualisation: clustering 3,250 mouse mononuclear phagocytes 1603 
(mMP) and 10,737 human mononuclear phagocytes (hMP) into 5 clusters (colour and 1604 
number) using canonical correlation analysis (CCA). Annotation of cross-species 1605 
clusters (identity). i, t-SNE visualisations: human and mouse macrophage 1606 
subpopulation annotation. j, t-SNE visualisations: selected genes expressed in cross-1607 
species clusters. Error bars, s.e.m.; ** p-value < 0.01; *** p-value < 0.001.  1608 
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Extended Data Figure 7: Scar-associated macrophage expansion in human 1609 
NASH 1610 
a to d, Deconvolution: publicly available whole liver microarray data (n=73) assessed 1611 
for frequency of scar-associated macrophages (SAM), Kupffer cells (KC) and tissue 1612 
monocytes (TMo) using Cibersort algorithm. a, Macrophage composition: x-axis, GEO 1613 
accession number; y-axis, fraction of monocyte-macrophages; Top, annotated by liver 1614 
phenotype; NASH, Non-alcoholic steatohepatitis. b, Frequency of SAM in control 1615 
(n=14), heathy obese (n=27), steatosis (n=14) and NASH (n=18) livers, Kruskal-Wallis 1616 
and Dunn. c, Frequency of SAM in patients with histological NAFLD activity score 1617 
(NAS) of 0 (n=37), 1-3 (n=19) and 4-7 (n=17) (left). Frequency of SAM in patients 1618 
with histological fibrosis score of 0 (n=46), 1 (n=20) and 2-4 (n=5) (right), Kruskal-1619 
Wallis and Dunn. d, Frequency of SAM in female (n=58) and male (n=15) patients 1620 
(left). Frequency of SAM in patients aged 23-39 (n=22), 40-49 (n=29) and 50-80 (n=22) 1621 
(middle). Frequency of SAM in patients with a body mass index (BMI) of 17-30 (n=18), 1622 
31-45 (n=28) and 46-70 (n=27) (right). All Kruskal-Wallis and Dunn. e, CD9 and 1623 
TREM2 staining in NASH liver biopsy sections (left). Automated cell counting (right): 1624 
CD9 staining, NAS 1-3 (n=13) versus NAS 4-8 (n=21). TREM2 staining, NAS 1-3 1625 
(n=12) versus NAS 4-8 (n=16), Mann-Whitney. f, Correlation of automated cell counts 1626 
with picrosirius red (PSR) digital morphometric pixel quantification in NAFLD liver 1627 
biopsy tissue; CD9 staining (top; n=39); TREM2 staining (bottom; n=32); Pearson 1628 
correlation and linear regression. Scale bars, 50μm. Error bars, s.e.m.; * p-value < 0.05, 1629 
















































































































































































































































































Extended Data Figure 8: Phenotypic characterisation of endothelial cells in 1631 
healthy and cirrhotic human livers. 1632 
a, t-SNE visualisations: clusters and selected genes expressed in endothelial lineage. b, 1633 
Violin plots: endothelial cluster marker genes. c, Digital morphometric pixel 1634 
quantification: PLVAP stained cirrhotic sections (n=10) morphologically segmented 1635 
into fibrotic septae and parenchymal nodules (top); ACKR1 stained cirrhotic sections 1636 
(n=10) morphologically segmented into fibrotic septae and parenchymal nodules 1637 
(bottom), Wilcoxon. d, Flow cytometry: endothelial cells from healthy (n=3) or 1638 
cirrhotic (n=7) liver, representative histogram for stated marker (top), mean 1639 
fluorescence intensity (MFI, bottom), Mann-Whitney. e, Flow-based adhesion assay: 1640 
peripheral blood monocytes were assessed for adhesion (left) and % of adherent cells 1641 
which transmigrate (right); endothelial cells from healthy (n=5) or cirrhotic (n=4) liver, 1642 
Mann-Whitney. f, Endothelial cell gene knockdown: cirrhotic endothelial cells treated 1643 
with siRNA to PLVAP (n=6), ACKR1 (n=5) or control siRNA (n=6). Representative 1644 
flow cytometry histograms for stated marker (top); comparison to isotype control 1645 
antibody. Flow-based adhesion assay (bottom), peripheral blood mononuclear cells 1646 
assessed for adhesion (bottom left) and % of adherent cells which transmigrate (bottom 1647 
right) following siRNA treatment of endothelial cells, Kruskal-Wallis and Dunn. g, 1648 
Self-Organising Map (SOM; 60 x 60 grid; top left): smoothed scaled metagene 1649 
expression of endothelia lineage. 21,237 genes, 3,600 metagenes, 45 signatures. A-E 1650 
label metagene signatures overexpressed in one or more endothelial subpopulations. 1651 
SOM: smoothed mean metagene expression profile for each endothelial subpopulation 1652 
(top right). Radar plots (bottom left): metagene signatures A-E showing distribution of 1653 
signature expression across endothelial subpopulations, exemplar genes (bottom 1654 
middle) and Gene Ontology (GO) enrichment (bottom right). h, t-SNE visualisation: 1655 
endothelia subpopulation annotation, injury condition. i, t-SNE visualisation: 1656 
endothelial lineage annotated by monocle pseudotemporal dynamics (purple to yellow; 1657 
grey indicates lack of inferred trajectory). RNA velocities (red arrows) visualised using 1658 
Gaussian smoothing on regular grid. Error bars, s.e.m.; * p-value<0.05; ** p-value < 1659 
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Extended Data Figure 9: Characterisation of mesenchymal cells in healthy and 1661 
cirrhotic human livers. 1662 
a, t-SNE visualisations: selected genes expressed in mesenchymal lineage. b, t-SNE 1663 
visualisation: clustering 319 scar-associated mesenchymal cells (SAMes), into 2 further 1664 
subclusters (colour and number). c, Scaled heatmap (red, high; blue, low): SAMes 1665 
subcluster marker genes (top, colour coded by cluster and condition), exemplar genes 1666 
labelled (right). Cells columns, genes rows. d, Fractions of SAMes subpopulations in 1667 
healthy (n=4) versus cirrhotic (n=3) livers, Wald. e, Representative 1668 
immunofluorescence micrograph, portal region of healthy liver: OSR1 (red), Collagen 1669 
1 (green), DAPI (blue). e, Representative immunofluorescence micrograph, fibrotic 1670 
niche of cirrhotic liver: OSR1 (red), Collagen 1 (green), DAPI (blue). g, t-SNE 1671 
visualisation: Hepatic stellate cell (HSC) and SAMes clusters annotated by monocle 1672 
pseudotemporal dynamics (purple to yellow). RNA velocity field (red arrows) 1673 
visualised using Gaussian smoothing on regular grid. h, Scaled heatmap (red, high; blue 1674 
low): cubic smoothing spline curves fitted to genes differentially expressed across 1675 
HSC-to-SAMes pseudotemporal trajectories, grouped by hierarchical clustering (k=2). 1676 
Colour coded by pseudotime and condition (top). Gene co-expression modules (colour) 1677 
and exemplar genes labelled right. Scale bars, 50μm. Error bars, s.e.m.; *** p-value < 1678 
0.001. 1679 
  1680 
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Extended Data Figure 10: Characterisation of the cellular interactome in the 1681 
fibrotic niche. 1682 
a, Circle plot: potential interaction magnitude from ligands expressed by scar-1683 
associated macrophages (SAM) and endothelial cells (SAEndo) to receptors expressed 1684 
on scar-associated mesenchyme (SAMes). b, Circle plot: potential interaction 1685 
magnitude from ligands expressed by SAMes to receptors expressed on SAM and 1686 
SAEndo. c, Dotplot: ligand-receptor interactions between SAMes, SAM and SAEndo. 1687 
X-axis, ligand (red) and cognate receptor (blue); y-axis, ligand (red) and receptor (blue) 1688 
expressing cell populations; circle size, p-value; colour (red, high; yellow, low), means 1689 
of average ligand and receptor expression levels in interacting subpopulations. d, 1690 
Representative immunofluorescence micrographs, fibrotic niche in cirrhotic liver. Top; 1691 
CCL2 (red), CCR2 (white), PDGFRα (green), DAPI (blue), arrows CCL2+PDGFRα+ 1692 
cells. Bottom; ANGPT1 (red), TEK(white), PDGFRa (green), DAPI (blue), arrows 1693 
ANGPT1+PDGFRa+ cells. e, Circle plot: potential interaction magnitude from ligands 1694 
expressed by SAM to receptors expressed on SAEndo. f, Dotplot: ligand-receptor 1695 
interactions between SAM and SAEndo. X-axis, ligand (red) and cognate receptor 1696 
(blue); y-axis, ligand (red) and receptor (blue) expressing cell populations; circle size, 1697 
p-value; colour (red, high; yellow, low), means of average ligand and receptor 1698 
expression levels in interacting subpopulations. g, Representative immunofluorescence 1699 
micrographs, fibrotic niche in cirrhotic liver. TREM2 (red), FLT1 (white), VEGFA 1700 
(green), DAPI (blue), arrows TREM2+VEGFA+ cells. h, Circle plot: potential 1701 
interaction magnitude from ligands expressed by SAEndo to receptors expressed on 1702 
SAM. i, Dotplot: ligand-receptor interactions between SAEndo and SAM. X-axis, 1703 
ligand (red) and cognate receptor (blue); y-axis, ligand (red) and receptor (blue) 1704 
expressing cell populations; circle size, p-value; colour (red, high; yellow, low), means 1705 
of average ligand and receptor expression levels in interacting subpopulations. j, 1706 
Representative immunofluorescence micrographs, fibrotic niche in cirrhotic liver. Top; 1707 
TREM2 (red), CD200 (white), CD200R (green), DAPI (blue), arrows 1708 
TREM2+CD200R+ cells. Bottom; TREM2 (red), DLL4 (white), NOTCH2 (green), 1709 
DAPI (blue), arrows TREM2+NOTCH2+ cells.  Scale bars, 50μm. 1710 
 1711 
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